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*      *       *
In everything I want to reach
The fundamental:
In work, in depth of inner speech,
In sentimental.
To probe the truth of days bygone,
And their essence,
The pondering, the bone,
And life’s core lessons.
The path of destiny, of fate
To reach and to uncover,
To live, to think, to meditate,
And to discover.
Oh, if I only could sumprise
After a fashion,
In eight lines I would summarize
The parts of passion.
The illegalities, the crimes,
Escape and chase force,
The accidents within the drives,
The palms, the elbows.
Its origin and law I would define,
In terms judicial,
The names it swears in,
And its initials.
My rhyme would throb and thrive
With fever ardent,
Due to the linden sap, alive,
As if it were a garden.
The essence of the rose, the mint,
The fragrance of the sedge,
The field in stormy glint,
Would give my verse an edge.
So did Chopin in his etudes
Miraculously conjure,
Groves, graves, and solidary moods -
A living wonder.
Triumph, attained through merriment,
Distress and throe,
Is like the arrow vibrant
Of the bow.
1956
                                     Boris Pasternak (1890-1960)
4ABSTRACT
Introduction: The epidemic of obesity
has been accompanied by an increase in
the prevalence of the metabolic
syndrome, type 2 diabetes, and non-
alcoholic fatty liver disease (NAFLD).
However, not all obese subjects develop
these metabolic abnormalities. Hepatic
fat accumulation is related to hepatic
insulin resistance, which in turn leads to
hyperglycemia, hypertriglyceridemia,
and a low HDL cholesterol con-
centration. The present studies aimed to
investigate 1) how intrahepatic as
compared to intramyocellular fat is
related to insulin resistance in these
tissues and to the metabolic syndrome
(Study  I);  2)  the  amount  of  liver  fat  in
subjects with and without the metabolic
syndrome, and which clinically available
markers best reflect liver fat content
(Study  II);  3)  the  effect  of  liver  fat  on
insulin clearance (Study III); 4) whether
type 2 diabetic patients have more liver
fat than age-, gender-, and BMI-matched
non-diabetic subjects (Study IV); 5) how
type 2 diabetic patients using
exceptionally high doses of insulin
respond to addition of a PPAR? agonist
(Study V).
Subjects and methods: The  study
groups consisted of 45 (Study I), 271
(Study II), and 80 (Study III) non-
diabetic subjects, and of 70 type 2
diabetic patients and 70 matched control
subjects (Study IV). In Study V, a total
of 14 poorly controlled type 2 diabetic
patients treated with high doses of
insulin were studied before and after
rosiglitazone treatment (8 mg/day) for 8
months. In all studies, liver fat content
was measured by proton magnetic
resonance spectroscopy, and sub-
cutaneous and intra-abdominal fat
content by MRI. In addition, circulating
markers of insulin resistance and serum
liver enzyme concentrations were
determined. Hepatic (i.v. insulin infusion
rate 0.3 mU/kg·min combined with [3-
3H]glucose, Studies I, III, and V) and
muscle (1.0 mU/kg·min, Study I) insulin
sensitivities were measured by the
euglycemic hyperinsulinemic clamp
technique.
Results: Fat accumulation in the liver
rather than in skeletal muscle was
associated with features of insulin
resistance, i.e. increased fasting serum
(fS) triglycerides and decreased fS-HDL
cholesterol, and with hyperinsulinemia
and low adiponectin concentrations
(Study I). Liver fat content was 4-fold
higher in subjects with as compared to
those without the metabolic syndrome,
independent of age, gender, and BMI.
FS-C-peptide was the best correlate of
liver fat (Study II). Increased liver fat
was associated with both impaired
insulin clearance and hepatic insulin
resistance independent of age, gender,
and BMI (Study III).  Type 2 diabetic
patients had 80% more liver fat than
age-, weight-, and gender-matched non-
diabetic subjects. At any given liver fat
content, S-ALT underestimated liver fat
in the type 2 diabetic patients as
compared to the non-diabetic subjects
(Study IV). In Study V, hepatic insulin
sensitivity increased and glycemic
control improved significantly during
rosiglitazone treatment. This was
associated with lowering of liver fat (on
the average by 46%) and insulin
requirements (40%).
Conclusions: Liver fat is increased both
in the metabolic syndrome and type 2
diabetes independent of age, gender, and
BMI. A fatty liver is associated with
both hepatic insulin resistance and
impaired insulin clearance. Rosi-
glitazone may be particularly effective in
type 2 diabetic patients who are poorly
controlled despite using high insulin
doses.
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1. INTRODUCTION
The metabolic syndrome represents a
cluster of risk factors which is thought to
increase the risk of cardiovascular
diseases and type 2 diabetes more than
the individual components (abdominal
obesity, increased serum triglycerides,
low HDL cholesterol, hyperglycemia,
and hypertension) (9). The patho-
physiology of the metabolic syndrome is
believed to include insulin resistance,
but it is poorly understood why some but
not others develop the syndrome. In
addition, the contribution of insulin
resistance and fat accumulation in the
liver and skeletal muscle to features of
the metabolic syndrome is unclear.
It has been estimated that approximately
70-80% of type 2 diabetic patients have
a fatty liver due to non-alcoholic causes
(18, 414). In addition, 11 prospective
epidemiological studies have shown that
elevated serum liver enzyme con-
centrations predict type 2 diabetes
independent of obesity (15, 172, 239,
240, 288, 289, 302, 314, 365, 443, 447).
The data would thus suggest that liver fat
content is increased in patients with type
2 diabetes as compared to equally obese
non-diabetic subjects. There are,
however, no data to prove or disprove
this hypothesis at present.
The liver is the primary site of insulin
clearance (116). In vitro, hepatocytes
loaded with triglycerides exhibit
impaired insulin clearance (400). Liver
fat is closely correlated with fasting
serum insulin concentrations (452), but
the extent to which impaired insulin
clearance due to hepatic fat ac-
cumulation contributes to hyper-
insulinemia has not previously been
determined.
A key action of insulin is to inhibit
hepatic glucose production (467). Once
fatty, the liver is insulin resistant to this
action of insulin both in normal subjects
(379) and patients with type 2 diabetes
(355).  Liver  fat  is  an  important  de-
terminant of insulin requirements during
insulin therapy in patients with type 2
diabetes (204, 355). Thus, type 2
diabetic patients with a fatty liver may
remain poorly controlled despite high
doses of insulin. This could be due to the
inability of insulin to act in a fatty liver.
Given that PPAR? agonists reduce liver
fat (21, 29, 63, 273, 424), it could be
hypothesized that patients requiring high
doses of insulin are particularly
responsive to PPAR? agonist treatment.
The present studies aimed to investigate
how liver fat content is related to the
metabolic syndrome, type 2 diabetes,
directly measured hepatic and whole-
body insulin sensitivity and clearance,
and circulating markers of insulin
resistance, such as insulin itself. We also
determined the impact of impaired
insulin clearance on serum insulin
concentrations, and the effect of a
PPAR? agonist treatment on liver fat and
hepatic insulin sensitivity in type 2
diabetic patients using exceptionally
high doses of insulin.
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2. REVIEW OF THE LITERATURE
2.1. INSULIN ACTION
Insulin is a peptide hormone which has
numerous metabolic actions in several
tissues (Table 1). It regulates glucose
metabolism by inhibiting glucose
production in the liver, and by
stimulating glucose uptake, particularly
in skeletal muscle (467). Insulin action
on lipid metabolism includes stimulation
of lipogenesis in adipose tissue and the
liver, and inhibition of lipolysis and
hepatic very low density lipoprotein
(VLDL) production (248, 416, 464,
467). In addition, insulin has effects on
vascular function, which include
diminishing the stiffness of large or
conduit arteries (455), and the induction
of slow vasodilatation in peripheral
resistance vessels (23, 465).
      Table 1. Metabolic actions of insulin in major target tissues.
Fuel Action of insulin Liver Muscle Adipose tissue
Glucose transport - ? ?
Glucose phosphorylation ? ? ?
GLUCOSE Glycogen synthesis ? ? ??]
Glycogen breakdown ? ? ??]
Glycolysis ? ? ?
Gluconeogenesis ?
De novo lipogenesis ? ??] ?
Oxidation of fatty acids ? ??] ?
LIPID Lipolysis ??] ?
VLDL production ?
Ketogenesis ?
Amino acid transport ? ? ?
PROTEIN Release of amino acids ? ?
Protein synthesis ? ? ??]
Protein breakdown ? ? ??]
      Adapted from ref. 469 with permission.
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2.1.1. Insulin action in the liver
2.1.1.1. Glucose metabolism
The liver can take up glucose (93, 96) or
produce it (466) via gluconeogenesis and
glycogenolysis (69, 95).
2.1.1.1.1. Methodological aspects
In humans, hepatic glucose metabolism
can be studied using stable and
radioactive tracers (345), the hepatic
venous catheterization technique (44,
129, 285), nuclear  magnetic resonance
(261, 352), or by a combination of
several techniques (96, 356).
With tracer methodology, the rate of
endogenous glucose production, which
can occur both in the liver and kidneys
(402), can be quantitated (345). How-
ever, the net contribution of the kidneys
to endogenous glucose production after
an overnight fast in humans is negligible
(35). Therefore, the term hepatic glucose
production (HGP) is used instead of
endogenous glucose production through-
out this thesis. The most commonly used
tracer for measuring hepatic glucose
production is [3-3H]glucose (467), which
is  handled  by  body  tissues  similarly  to
cold (unlabeled) glucose (471). The
labeled tritium is lost during glycolysis
as a water molecule but not during
glucose incorporation in or release from
hepatic glycogen (460). Plasma glucose
specific activity (SA) can therefore be
determined after evaporating water from
deproteinized plasma samples (460).
Under steady-state conditions, when
both plasma glucose SA and con-
centrations are constant, the rate of HGP
can be accurately calculated from the
following equation:
HGP = Isotope infusion rate/plasma
glucose SA
When the entry of either endogenous or
exogenous glucose into the circulation
occurs, the specific activity of glucose
changes (154). During low-dose hyper-
insulinemic euglycemic clamp (104),
when hepatic glucose production is half-
maximally suppressed (96, 348, 467,
478), total glucose rate of appearance
(Ra) is a sum of endogenous (hepatic)
and exogenous glucose Ra:
Ra = HGP + Ra exo
The total rate of glucose Ra is most
frequently calculated using the one-
compartment model equations of Steele
(393):
Ra = (Isotope infusion rate / mean
plasma glucose SA) – (p ? V ? mean
plasma glucose ?? ?SA / [mean plasma
glucose SA ???Time])
where p is a pool fraction of distribution
of glucose, V is the distribution volume
for glucose, and ?SA and ?Time
represent the changes in glucose specific
activity over time (393). Under non-
steady-state conditions, HGP can thus be
calculated from the following equation:
HGP = Ra - Ra exo
The one compartment model is based on
the assumption that there is a single
homogenous pool in the body where
labeled and unlabeled glucose mix
instantaneously and uniformly (393,
460), and that the labeled glucose cannot
re-enter the glucose pool after it has left
the pool (460). These assumptions are
not always true (13, 136). For example,
during hyper-insulinemic euglycemic
13
clamp experiments, the glucose pool
enlarges (136).  Because of the inability
of one-compartment model to describe
the whole body glucose kinetics
accurately, glucose production is
underestimated when glucose specific
activity decreases (467), which results in
physiologically impossible negative rates
of the suppression of hepatic glucose
production by insulin (31, 138, 471).
Other approaches have been used to try
to better characterize the non-steady
state kinetics of glucose, but despite the
increased sophistication of the new
approaches (77), the Steele equation has
remained the standard for calculation of
non-steady state kinetics.
The catheterization technique allows
assessing net splanchnic glucose balance
by multiplying the arterial - hepatic vein
glucose difference by blood flow (44,
129, 285). Since net hepatic glucose
balance represents the difference
between hepatic glucose production and
splanchnic glucose uptake, this tech-
nique is unable to separately quantitate
these processes (97). Therefore, if glu-
cose production is measured in a
hyperglycemic subject, net splanchnic
balance may appear normal because of
simultaneous increases in splanchnic
glucose uptake and hepatic glucose
production (96, 97). These processes can
be quantitated separately by combining
the catheterization technique with use of
a tracer (129, 131). Invasiveness limits
widespread use of the catheterization
technique.
Hepatic glycogen content can be
measured with 13C nuclear magnetic
resonance spectroscopy in vivo (261,
352). The rate of gluconeogenesis can be
calculated by subtracting the rate of
glycogenolysis from total endogenous
glucose production (261). Use of
[18F]fluorodeoxyglucose ([18F]FDG) and
positron emission tomography (PET) for
quantification of hepatic glucose uptake
has been evaluated in humans (194) and
recently validated in pigs (195).
2.1.1.1.2. Normal actions of insulin
After an overnight fast, the liver is the
major source of endogenously produced
glucose (35, 44), and is therefore the
primary organ determining plasma glu-
cose concentrations when serum insulin
concentrations are low. Dose-response
studies relating plasma insulin to the
suppression of hepatic glucose produc-
tion have indicated that the liver is
extremely sensitive to small increments
in serum insulin concentrations (96, 348,
467, 478). Complete suppression of he-
patic glucose production occurs at
peripheral insulin concentrations of 50-
60 mU/l (96, 348, 478). Half-maximal
suppression of hepatic glucose produc-
tion in different studies of non-diabetic
subjects has been reported to occur at
serum insulin concentrations of 11-46
mU/l (61, 96, 162, 163, 346, 348).
Insulin can inhibit hepatic net glucose
release via a variety of mechanisms. This
occurs mainly via inhibition of glucose
production (96). Insulin also stimulates
glucose uptake, the magnitude of which
depends on whether glucose is given
orally (282) or intravenously (97, 101).
The mechanisms include the stimulation
of the glucokinase activity (325), and a
decrease in glucose-6-phosphatase activ-
ity (34, 183, 438). In addition, insulin
can stimulate glycogen synthesis (179,
459), inhibit glycogen breakdown (321,
459), and suppress gluconeogenesis (24).
Studies in humans have indicated that
the suppression of glycogenolysis is
more sensitive to insulin than is the
suppression of gluconeogenesis (7, 39,
151). A recent study in non-diabetic
14
subjects indicated that a stepwise in-
crease in serum insulin concentrations
from ~13 mU/l to ~25 mU/l decreases
hepatic glucose production via suppres-
sion of glycogenolysis, while the rate of
gluconeogenesis remains unchanged (7).
Under normoglycemic conditions,
splanchnic glucose uptake is not stimu-
lated by insulin, even at supra-
physiological insulin concentrations of
~1200 mU/l (96). Hyperglycemia is a
powerful stimulator of splanchnic glu-
cose uptake independent of serum
insulin concentrations (96).
2.1.1.1.3. Insulin action in insulin-
resistant subjects
Obese subjects. When obese normo-
glycemic subjects have been compared
to lean non-diabetic individuals, basal
hepatic glucose production has been
reported to be similar in both groups (42,
103, 149). However, this does not
exclude hepatic insulin resistance, since
obese  subjects  often  are  hyper-
insulinemic as compared to non-obese
ones (42, 103, 149). Consistent with this,
the ability of insulin to suppress hepatic
glucose production has been shown to be
either impaired (42, 103, 309) or similar
(164) in the face of higher serum insulin
concentrations during exogenously
induced hyperinsulinemia in obese as
compared to lean subjects.
Subjects with a fatty liver. To date, only
two cross-sectional studies have
examined the effect of hepatic fat
accumulation on hepatic glucose
production in non-diabetic subjects using
low-dose insulin infusion euglycemic
hyperinsulinemic clamp technique (55,
379). The % suppression of hepatic
glucose production by insulin was either
significantly impaired (379) or similar
(55)  in  subjects  with  a  fatty  liver  as
compared to equally obese control
subjects. Marchesini et al found hepatic
insulin sensitivity, measured using
euglycemic hyperinsulinemic clamp of a
standard insulin infusion rate (1
mU/kg·min (104)), to be impaired in
obese subjects with a biopsy-proven
fatty liver as compared to lean controls
(268). It has thus remained uncertain
whether hepatic fat accumulation
associates with hepatic insulin resistance
independent of obesity in non-diabetic
subjects.
Type 2 diabetic patients. Numerous
studies have indicated the inability of
insulin to suppress hepatic glucose
production in the fasting state to be a
primary cause of fasting hyperglycemia
in patients with type 2 diabetes (41, 61,
80, 91, 92, 98, 466). Hepatic insulin
sensitivity has been shown to be
decreased in obese type 2 diabetic
patients as compared to non-obese non-
diabetic subjects (164, 214, 303), but
when age-, gender-, and weight-matched
groups have been compared, hepatic
insulin resistance has frequently been
reported to be comparable (14, 26, 164,
309, 391, 430). Several studies have
reported an inverse relationship between
hepatic insulin sensitivity and hepatic fat
accumulation (21, 150, 214), but
whether these associations are independ-
ent of obesity remains to be determined
(21, 150, 214).
Other conditions. Hepatic insulin action
on glucose production has been reported
to be impaired in patients with acute
infections (441), acromegaly (173, 283),
hyperthyroidism (380), and in patients
after major uncomplicated surgery (48),
but not in patients with Cushing’s
syndrome (178), essential hypertension
(350), or liver cirrhosis (322, 335).
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2.1.1.2. Lipid metabolism
2.1.1.2.1. Methodological aspects
VLDL kinetics. The relative changes in
VLDL triglyceride and VLDL
apolipoprotein B (ApoB) production
rates can be determined using tracer
techniques (460). This approach involves
examining the change in specific activity
of exogenously administrated isotopi-
cally labeled amino acids (85, 140, 193,
266) or glycerol (4, 165), which are then
incorporated into newly synthesized
VLDL particles. Another option is to use
the exogenous labeling of the lipoprotein
particles of interest using either 125I or
131I isotopes (390, 417). The infusion of
these particles in the circulation allows
following both kinetics and the
interconversion and catabolic rates of the
lipoprotein particles.
Splanchnic lipid oxidation. By using the
combination of hepatic venous cathe-
terization technique (44, 129, 285), the
infusion of labeled fatty acids (162, 196,
449), indirect calorimetry (130), and the
measurements of breath CO2 carbon
specific activity (162, 196, 449),
splanchnic fatty acid oxidation can be
measured directly (385, 386).
2.1.1.2.2. Normal actions of insulin
In non-diabetic healthy subjects, insulin
(1 mU/kg·min) decreases hepatic VLDL
triglyceride and ApoB production by
~50% (248-250). This effect of insulin
appears to some extent independent of
serum FFA concentrations (249), since
the maintenance of fasting FFA con-
centrations despite hyperinsulinemia
attenuates the suppression of VLDL
production (249). Hyperinsulinemia
lowers plasma VLDL concentrations
primarily by suppressing the production
of large, triglyceride-rich VLDL1
particles, while the production of dense
VLDL2 particles remains unchanged
(266).
Although in vitro studies  have  shown
insulin to inhibit both hepatic fatty acid
oxidation and de novo lipogenesis (227,
274), there are no human studies
examining the direct effects of insulin on
these metabolic processes. One study
including five healthy subjects indicated
the combination of hyperglycemia and
hyperinsulinemia inhibits splanchnic
fatty acid oxidation (385). Serum
concentrations of a ketone body 3-
hydroxybutyrate (3-OHB), a surrogate
marker of hepatic fatty acid oxidation
(25, 145, 177), have been shown to
decrease during the low-dose euglyce-
mic hyperinsulinemic clamp (55, 127,
237).
2.1.1.2.3. Insulin action in insulin-
resistant subjects
The acute inhibitory effect of insulin on
VLDL production is significantly
impaired in obese as compared to lean
subjects (248). When two groups of non-
diabetic subjects and type 2 diabetic
patients accurately matched for age,
gender, and obesity have been compared,
insulin suppression of VLDL1 but not
VLDL2 production have been found to
be impaired under both hyperglycemic
and normoglycemic conditions (265).
Recently, the ability of insulin to
suppress VLDL1 production has been
shown to be impaired in subjects with
high as compared to those with low liver
fat  content  (6).  However,  since  the
subjects with high liver fat content were
more obese and had higher serum FFA
concentrations during the insulin infu-
sion than those with low liver fat content
(6), it  remained unclear whether the link
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between hepatic fat accumulation and
the impaired ability of insulin to
suppress VLDL production is independ-
ent of the above factors.
Serum concentrations of 3-OHB have
been shown to be higher in the basal
state in subjects with non-alcoholic fatty
liver disease (NAFLD) as compared to
either lean (361) or weight matched (55)
control subjects. In these studies, the
ability of insulin to lower 3-OHB
concentrations during the low-dose
insulin infusion was comparable
between the two groups, but serum 3-
OHB concentrations remained signifi-
cantly  higher  in  subjects  with  a  fatty
liver as compared to controls (55, 361).
Whether insulin action on hepatic lipid
oxidation differs in other insulin resistant
states,  such  as  obesity  and  type  2
diabetes, remains to be determined.
2.1.2. Insulin action in skeletal
muscle
2.1.2.1. Methodological aspects
The golden standard technique for
determining insulin sensitivity is the
euglycemic hyperinsulinemic clamp (16,
104). With this method, insulin is
administrated intravenously in a prime-
continuous fashion at a rate calculated
either per kg body weight or body
surface area (104). Euglycemia is
maintained by means of an exogenous
infusion of 20% glucose (104). At an
insulin infusion rate of 1 mU/kg·min (40
mU/m2·min), hepatic glucose production
is completely suppressed in normal
subjects (96, 348, 478). Under these
conditions, the exogenous glucose
infusion rate corrected for changes in the
glucose pool size (M-value) equals the
amount of glucose disposed by all
tissues in the body (104). Under such
conditions, skeletal muscle accounts for
~70% of whole-body glucose disposal
(96, 297, 475, 478).
If insulin infusion rates lower than 1
mU/kg·min are used, the rate of hepatic
glucose production has to be taken into
account when determining glucose rate
of disappearance (Rd) (96, 348, 478).
Under non-steady-state conditions,
glucose Rd equals the difference between
total glucose Ra and a change in the total
amount of glucose over time:
Rd = Ra – p ? V ? ?Glucose / ?Time
where p is  a  pool  fraction  for  the
distribution of glucose and V its distribu-
tion volume (393).
Muscle glucose uptake can also be
determined using the femoral venous
catheterization technique (101). In addi-
tion, regional glucose uptake can be
measured using PET combined with a
positron-emitting radionuclide -labeled
glucose analogue (297, 442), such as
[18F]FDG (388).
Indirect calorimetry is a non-invasive
method to estimate rates of substrate
oxidation and energy expenditure at the
level of whole-body (87, 130). The rate
of carbohydrate oxidation can be
calculated from measurements of O2
consumption, CO2 production, and
protein oxidation (urinary nitrogen
excretion) (87, 130). If the respiratory
quotient (the ratio of the carbon dioxide
production and oxygen consumption, RQ
= VCO2/VO2) is measured across the leg
or arm, the rate of muscle substrate
oxidation can be estimated (216, 444).
Non-oxidative glucose disposal, which
represents the sum of glycogen storage
and non-oxidative glycolysis (467), can
be calculated by subtracting the rate of
carbohydrate oxidation from the rate of
glucose disposal.
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2.1.2.2. Normal actions of insulin
After an overnight fast, glucose
utilization is mainly non-insulin
dependent (168, 467). Under these
conditions, more than half of glucose is
utilized by the brain (168, 353, 366,
367), approximately one fourth by
splanchnic area (96), and one tenth by
the heart, adipose tissue, and kidneys
(35, 38, 349). Thus, only approximately
10% of glucose utilization occurs in
skeletal muscle under overnight fasted
conditions (467).
Insulin stimulates glucose utilization
predominantly in skeletal muscle (96,
297, 475, 478) by stimulating the
translocation of insulin-sensitive glucose
transporter GLUT-4 from intracellular
sites to the plasma membrane (167, 224).
In humans, glucose utilization is half-
maximally stimulated at serum insulin
concentrations of 48-130 mU/l (mean 77
mU/l) (61, 96, 226, 267, 348, 420), when
measured using euglycemic hyper-
insulinemic clamp technique (104).
Maximal glucose utilization, which is
approximately six times the rate
measured after an overnight fast (267,
348, 420, 467), occurs at serum insulin
concentrations of ~200 mU/l in normal
subjects (267, 348, 420).
Insulin increases both oxidative and non-
oxidative disposal of glucose. Half-
maximal stimulation of glucose
oxidation is achieved by insulin
concentrations of 22-50 mU/l (43, 162,
267, 420, 470, 480). Non-oxidative glu-
cose disposal is less sensitive to insulin,
since half-maximal stimulation occurs at
insulin concentrations of 75-150 mU/l
(162, 267, 420, 480). The capacity of
body tissues to utilize glucose non-
oxidatively is 1.2-2.4 –fold higher than
the capacity to oxidize glucose (267,
478, 480).
2.1.2.3. Insulin action in insulin
resistant-subjects
Obese subjects.  Insulin resistance
generally increases with increasing
obesity. According to the European
Group for the study of Insulin Resistance
(EGIR) database, which includes
measurements of insulin sensitivity by
the euglycemic hyperinsulinemic clamp
in over a thousand of healthy non-
diabetic European men and women, BMI
is a strong determinant of insulin
sensitivity (462). However, variation in
BMI  accounts  for  only  part  of  the
variance in insulin sensitivity (462).
Thus, the degree on insulin resistance
varies considerably among equally obese
subjects, and even lean subjects can be
insulin resistant. Obesity and skeletal
muscle insulin resistance are associated
with reduced muscle capillary density
(251), an increase in the proportion of
glycolytic type IIb and a decrease in
oxidative type I muscle fibers (230,
251), and structural changes in skeletal
muscle fatty acid membrane composition
(230). Whether these changes are a cause
or a consequence of obesity remains to
be determined. In addition, serum FFA
concentrations may contribute to skeletal
muscle insulin resistance (215, 281).
Type 2 diabetic patients. Using  the
insulin clamp technique (104) with
insulin infusion of 1 mU/kg·min in
combination with femoral vein/artery
catheterization to quantitate leg glucose
uptake, the onset of insulin action on
glucose uptake has been shown to be
delayed and leg glucose uptake reduced
by 40-50% in type 2 diabetic patients as
compared to weight-matched non-
diabetic subjects (99). Similar results
have been reported using the forearm
catheterization technique (61, 62, 207,
282). Both glucose oxidation and non-
oxidative glucose disposal are impaired
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in patients with type 2 diabetes (92,
155). Insulin binding to skeletal muscle
has been reported to be similar in type 2
diabetic patients and non-diabetic
subjects (299), whereas intracellular
insulin receptor cascade differs between
these groups (299). The postreceptor
defects in skeletal muscle include
reduced insulin receptor kinase activity
(299) and translocation of glucose
transporters (37), and impaired phos-
phorylation of insulin receptor second
messengers, such as insulin receptor
substrate 1 (IRS-1) (36, 37, 86) and
phosphatidylinositol 3-kinase (PI 3-
kinase) (36, 37, 86, 220).
Type 1 diabetic patients. Muscle insulin
resistance is a common feature of type 1
diabetes (100, 102, 105, 185, 341, 477).
Glucose toxicity, the harmful metabolic
effects of chronic hyperglycemia, is
regarded as a major cause of peripheral
insulin resistance in type 1 diabetic
patients (468).
Other conditions. Muscle insulin
sensitivity is impaired during acute
infections (441), acromegaly (199),
hyperthyroidism (200), primary hyper-
parathyroidism (332, 332), Cushing’s
syndrome (178), essential hypertension
(132), liver cirrhosis (202, 322, 335, 378,
439), and in patients after major uncom-
plicated surgery (48).
19
2.2. INSULIN CLEARANCE
Irreversible removal of a biological
compound occurs via excretion and
metabolism (116). In the case of insulin,
excretion is negligible, and therefore
removal is primarily the result of
degradation (116, 339).
2.2.1. Methodological aspects
Whole-body insulin clearance. At
steady-state, the rate of insulin removal
equals its rate of administration (66).
Thus, the kinetics of peripheral insulin
metabolism can be directly assessed
using the euglycemic hyperinsulinemic
clamp technique (104), assuming that the
contribution of endogenous insulin
secretion is negligible or suppressed
(94). The rate of insulin clearance is
calculated by dividing the insulin
infusion rate by steady-state arterialized
serum insulin concentrations (66).
Indirectly, insulin clearance can be
estimated from the plasma decay curves
after an acute intravenous insulin bolus
(66, 133).
Hepatic insulin extraction. Using hepatic
venous catheterization (129), the rate of
hepatic insulin extraction can be
calculated by dividing arterial - hepatic
venous insulin concentration difference
by the arterial insulin concentration
(137). C-peptide is secreted by the
pancreas at the same molar rate as
insulin, but is not extracted by the liver
to any significant amounts (221). Thus,
hepatic insulin extraction can non-
invasively be estimated from peripheral
insulin and C-peptide concentrations
using several mathematical models (66).
This assumes, however, that C-peptide
clearance does not display interindi-
vidual variation, which may not be the
case (124).
2.2.2. Sites of insulin clearance in
humans
Insulin is cleared from the circulation
mostly in the liver and kidney, and to a
lesser extent in muscle and adipose
tissue (116). In the fasting state,
approximately 40% and 15% of circulat-
ing insulin is removed by the liver and
kidney when measured using hepatic and
renal venous catheterization techniques
(137). After induction of hyper-
insulinemia, the respective proportions
rise to 50-80% (49, 137, 357, 445) and
20-30% (137).
2.2.3. Insulin clearance in humans
Endogenous insulin reaching the
systemic circulation through the hepatic
veins, or infusion of exogenous insulin
intravenously, is cleared from the plasma
at the rate of approximately 12
ml/kg·min. This translates into ~840
ml/min for a man weighting 70 kg (133,
134, 137, 381). Given that the coefficient
of variation of this estimate is over 20%
(290, 427, 428), the normal range can be
calculated to be 7-17 ml/kg min for 95%
of healthy population (133). The reasons
for this wide interindividual variation
have been poorly characterized.
2.2.4. Factors influencing insulin
clearance
Body composition. In normal-weight
subjects,  muscle  mass  increases  and
body fat decreases insulin clearance
(458, 474). Body composition explains
up to 37% of the interindividual
variation in directly measured whole-
body insulin clearance (474).
Obesity and body fat distribution. Insulin
clearance, expressed either per kg body
weight  or  per  body  surface  area,  has
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been decreased in most (45, 65, 123,
279, 351, 389, 488) although not all
(312, 326, 333) studies in obese as
compared to lean subjects. In studies
where insulin clearance was expressed
per kg fat free mass, insulin clearance
was unaltered by obesity (65, 488).
Several studies have suggested that intra-
abdominal rather than subcutaneous fat
influences insulin clearance (213, 312,
313) independent of BMI (312) because
of diminished hepatic insulin extraction
(213, 312, 313).
Insulin resistance and type 2 diabetes. A
decrease in insulin clearance has been
observed in insulin-resistant as com-
pared to age- and BMI-matched insulin-
sensitive subjects (203). In small groups
of type 2 diabetic patients, insulin
clearance has been reported to be normal
(150, 152, 327), decreased (146, 399),
and increased (305) compared to non-
diabetic subjects. The reasons of these
divergent results are unclear.
Hepatic fat accumulation. In vitro,
insulin clearance is impaired in
hepatocytes loaded with triglycerides
(400). In the in situ perfused rat livers,
insulin clearance is inversely related to
hepatic triglyceride content (406). In a
study of 46 non-diabetic subjects with a
wide range of adiposity, the liver-to-
spleen attenuation ratio (L/S ratio), a
qualitative marker of liver fat, was found
to be inversely related to insulin
clearance (159). In addition, we have
previously shown that decreasing liver
fat content by rosiglitazone increases
insulin clearance and enhances hepatic
insulin sensitivity independent of body
weight in type 2 diabetic patients (424).
Serum FFA. Wiesenthal et al showed
that in dogs hepatic insulin extraction is
impaired when serum FFA concentra-
tions are elevated to supraphysiological
concentrations by infusions of a soy-
based lipid emulsion and heparin during
euglycemic hyperinsulinemia (457). In
humans, a day-long infusion of a soy-
based lipid emulsion and heparin (S-FFA
~500-800 ?mol/l) has also been shown
to reduce insulin clearance in subjects
with a family history of type 2 diabetes
(212).
Advanced liver disease. Hyper-
insulinemia in patients with cirrhosis has
been attributed to both increased insulin
secretion and impaired hepatic insulin
extraction (197, 244, 298, 479). In a
study including patients with
compensated cirrhosis of different
etiologies, insulin secretion rate has been
shown to be 60% higher and insulin
clearance 40% lower in cirrhotic patients
as compared to age- and BMI-matched
subjects (244). In these patients, insulin
clearance was strongly positively related
to the magnitude of the portosystemic
shunt (244).
Kidney function. Uremia decreases
insulin clearance in humans (84, 301). In
one study using renal catheterization
technique, severe uremia reduced renal
insulin extraction from 39% to 9% (340).
Other factors. Hyperthyroidism in-
creases insulin clearance (78), which can
be normalized by anti-thyroid treatment
(293). In addition, patients with
Cushing’s syndrome exhibit a decrease
in insulin clearance (78). Some studies
have suggested impaired insulin clear-
ance to be a feature of essential
hypertension (153, 358).
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2.3. ECTOPIC FAT DEPOSITION
The deposition of fat into non-adipose
tissues, which have only a small
intracellular reserve of lipids, is termed
as ‘ectopic fat accumulation’ (143, 434).
These tissues include the liver, skeletal
muscle, the heart, and pancreas (434).
2.3.1. The liver
2.3.1.1. Definition
Typically, the liver stores approximately
100g of whole-body fat (143). NAFLD
refers to fat accumulation in the liver
exceeding 5% to 10% of liver weight
(17, 291). If measured by proton
magnetic resonance spectroscopy (1H-
MRS), liver TG greater than 5.6% (55.6
mg/g)  is  considered  abnormal,  as  it
corresponds to the 95th percentile of the
distribution of liver fat in subjects
(n=345) with normal S-ALT and fasting
glucose concentrations, and low alcohol
consumption (409). NAFLD comprises a
spectrum of liver pathology ranging
from simple steatosis to steatohepatitis
(1, 76), which may progress to cirrhosis
and hepatocellular carcinoma (291). By
definition, alcohol consumption should
not exceed 14 units/wk (20 g/d), and
viral (hepatitis B and C), toxic, autoim-
mune (clearly elevated antinuclear and
anti-smooth muscle antibodies), and
other causes of steatosis (Wilson disease,
hypobetalipoproteinemia) should be
excluded (53). The diagnosis of non-
alcoholic steatohepatitis (NASH) in-
cludes, in addition to macrovesicular
steatosis, lobular inflammation and
hepatocellular ballooning (291).
2.3.1.2. Pathogenesis
Despite attempts to understand the
mechanisms underlying NAFLD, the
pathogenesis remains poorly understood.
Lessons from in vivo studies in humans
The fatty acids in hepatic triglycerides
are derived from dietary chylomicron
remnants, FFA released from adipose
tissue, or from chylomicrons hydrolyzed
at a rate in excess of what can be taken
up by tissues (spillover), and from de
novo lipogenesis (311). Hepatic
triglycerides are secreted as VLDL or
oxidized via ?-oxidation (143, 462). In
subjects with NAFLD, 60% of
triacylglycerols stored in the liver are
derived from plasma FFA (112), while
catheterization studies have shown that
direct hepatic FFA delivery from
splanchnic lipolysis accounts for only
approximately 5-10% and 30% in the
fasting state in lean and obese subjects,
respectively (292). This implies that the
majority of fatty acids delivered to the
liver originates from subcutaneous
adipose tissue (222, 292). Postprandially,
the contribution of the spillover pathway
and uptake of chylomicron remnants
increase from 11% to 30% and can
account for approximately 60% of the
fatty acids secreted as VLDL-TG in
subjects with NAFLD (311). Further-
more, the contribution of de novo
lipogenesis to hepatic triglycerides ac-
counts for approximately 5% (310) in
normal subjects and 20-25% (109, 112)
in subjects with a fatty liver.
Postprandially, the rate of de novo
lipogenesis increases up to 23% in
normal subjects (426). This increase is
absent in subjects with NAFLD (112).
Approximately 10% and 20-40% of the
sources of FFA in the fasting and fed
states remained unknown in the latter
study using state-of-the-art triple stable
isotope methodology (112).
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Lessons from in vitro studies in humans
Gene expression in the liver. To date,
few studies have investigated alterations
in hepatic gene expression in patients
with NAFLD (47, 70, 354, 453, 481,
482). In two studies comparing subjects
with and without simple steatosis (453,
481), genes involved in liver regenera-
tion (481), magnesium carrying (481),
fatty acid binding (453), lipolysis (453),
and monocyte/macrophage recruitment
(453) were found to be significantly
upregulated independent of obesity also
after verification by real-time PCR
(481). When patients with NASH have
been compared to control subjects,
differential expression has been found in
mitochondrial and inflammatory genes,
as  well  as  in  genes  involved  in  insulin
signaling, defense against oxidative
stress, and de novo lipogenesis (47, 70,
354, 481, 482). However, these studies
have not found the same genes to be
altered,  and  only  a  few  of  these  genes
have been verified by real-time PCR (47,
70, 354, 481, 482).
Gene expression in adipose tissue. In
obese individuals, the number of
macrophages is increased and accompa-
nied by increased expression pro-
inflammatory factors, such as TNF?,
MCP-1, and IL-6 (46, 107, 450).
Recently, our group tested the
hypothesis that adipose tissue inflamma-
tion characterizes subjects with high
liver fat content independent of obesity
in weight-matched obese groups
differing with respect to liver fat content
(225). Adipose tissue from the group
with high liver fat content was inflamed
(225), and was characterized by an
increased number of macrophages
surrounding dead adipocytes (74, 225).
Lessons from animal studies
Animals with genetic or environmental
induction of hepatic fat accumulation
may provide insights into possible
molecular mechanisms involved in the
pathogenesis of NAFLD. Animals with
naturally occurring or genetically
induced mutations resulting in obesity
develop a fatty liver mainly because of
excess  FFA  flux  into  the  liver  and
induction of hepatic lipogenesis (228).
Transgenic models of inhibition of
hepatic fatty acid oxidation (125, 217),
VLDL assembly and secretion (192, 245,
338), overexpression of hepatic
lipogenic genes (228, 383), liver-specific
overexpression of lipoprotein lipase
(219), and overexpression of the nuclear
form of SREBP-1a in adipose tissue
(184) have been shown to develop
hepatic steatosis. Hepatic lipogenesis
induced by dietary sucrose (330),
fructose (330), and fat (228), and hepatic
fatty acid oxidation inhibited by dietary
choline- or methionine-deficient diets
(451) result in a fatty liver. However, the
relevance of these models for the
pathogenesis of the human fatty liver is
unclear.
2.3.1.3. Diagnostic methods
Stetosis
Liver biopsy. A liver biopsy is
considered the golden standard for
quantification of liver fat (223). How-
ever, due to ethical limitations, this
method cannot be routinely used for di-
agnosing NAFLD. An important draw-
back of liver biopsy, which represents
only 1:50000 of the total mass of the
liver (50), is sampling variability
resulting from the heterogeneous distri-
bution of histological lesions (262, 263).
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Table 2. Obesity-independent circulating markers of NAFLD.
Markers of NAFLD NAFLD/
Controls*
Subjects
characteristics**
Liver fat
methodology
Reference
hs-CRP?, HOMA-IR? 16/160 Age: 45 years
BMI: 26 kg/m2
Histology 413
IL-6?, MCP1?, CCL19? 22/30 Age: 48/42 years
BMI: 29/23 kg/m2
Histology 175
Coenzyme Q10?, SOD?,
catalase?, MDA?, S-ALT?, S-
AST?, fS-insulin?, C-peptide?,
HOMA-IR?, S-triglycerides?, S-
HDL cholesterol?
51/30 Age: 36 years
BMI: 28 kg/m2
Histology 461
Adiponectin?, HOMA?, fS-
insulin?, S-ALT?, S-AST?, S-
?GT?
17/20 Age: 44/42 years
BMI: 27 kg/m2
Histology 307
HOMA-IR?, adiponectin?,
resistin?
12/12 Age: 40/43 years
BMI: 30/29 kg/m2
Histology 12
TNF??, adiponectin?, S-ALT?,
fP-glucose?, fS-insulin?, C-
peptide?, HOMA-IR?
29/82 Age: 42/50 years
BMI: 30 kg/m2
Histology 188
Adiponectin?, HOMA-IR?,
QUICKI?, S-ALT?, S-AST?, S-
?GT?, fS-insulin?, S-HDL
cholesterol?, fS-FFA?
174/42 Age: 41/43 years
BMI: 27/28 kg/m2
Histology and
ultrasound
57
Factor VII clotting activity?,
PAI-1 activity and antigen?, t-PA
activity?
31/33 Age: 38 years
BMI: 27/24 kg/m2
Ultrasound 73
hs-CRP?, fibrinogen?, v-WF?,
PAI-1 activity?
35/65 Age: 41/43 years
BMI: 26/24 kg/m2
Ultrasound and CT 415
?2-Heremans-Schmid
glycoprotein/fetuin-A?
90 Age: 45 years
Body weight: 86 kg
1H-MRS 394
S-?GT? 70 Age: 41 years
BMI: 28 kg/m2
1H-MRS 419
Adiponectin? 242 Age: 46 years
BMI: 26-32 kg/m2
1H-MRS 210
fS-HDL cholesterol, fS-
triglycerides?, fS-FFA?, leptin?,
adiponectin?, resistin?. E-
selectin?
21/21 Age: 36/35 years
BMI: 28/27 kg/m2
1H-MRS 315
RBP-4? 75 Age: 44 years
Body weight: 87 kg
1H-MRS 395
* Number of subjects
** Age and BMI or body weight denote mean values
24
Imaging. On ultrasonography, a fatty markers is essentially similar to that of
liver  produces  a  diffuse  increase  in
echogenity and sound attenuation (337),
which is similar to that seen in fibrosis
and cirrhosis (67, 359). Magnetic reso-
nance imaging (139, 306) and the L/S
ratio determined by computed tomogra-
phy (387) provide qualitative rather than
quantitative estimates and their sensitiv-
ity is limited (387). Assessment of liver
fat content by 1H-MRS involves
recording of the two dominant peaks
within the unsuppressed magnetic reso-
nance spectrum: water at 4.7-4.8 ppm
and methylene at 1.0–1.5 ppm (254, 407,
422). Since the area under the peaks can
easily be quantitated, the % liver fat can
be calculated from the following
equation (355):
% liver fat = (area under the methylene
peak) / (area under the water peak +
area under the methylene peak) ? 100%
1H-MRS represents the most reliable
non-invasive method to measure liver fat
content at present (462).
Circulating markers. Serum liver
enzyme concentrations (S-ALT, S-AST)
have been shown to correlate with liver
fat content measured by 1H-MRS (452,
462), but normal S-ALT concentrations
do not exclude steatosis. Indeed, in
Dallas  Heart  Study,  in  which  liver  fat
content was determined using 1H-MRS
in 2287 subjects, normal S-ALT con-
centrations were present in 79% of the
subjects with a fatty liver (>5.6%) (52).
Several other obesity-independent mark-
ers  of  NAFLD  have  been  identified
(Table   2) .   The   sensitivity   of    these
S-ALT.
NASH
NASH can only be reliably diagnosed
using a liver biopsy (253). To date, only
a few obesity-independent circulating
markers of NASH have been reported in
cross-sectional studies of relatively small
size (Table 3). However, these markers
may not be specific to NASH.
Fibrosis
At  present,  the  presence  of  fibrosis  can
only be reliably established by a liver
biopsy, although several circulating and
anthropometric markers of fibrosis have
been proposed (166). A combination of
several  markers  may  be  more  useful  in
the diagnosis of fibrosis (19, 166, 308).
In a recent cross-sectional analysis of
733 patients with NAFLD, use of a
NAFLD fibrosis score predicted fibrosis
correctly in 90% (19). By applying this
score, which included age, hyper-
glycemia, body mass index, platelet
count, albumin, and the AST/ALT ratio,
a liver biopsy could be avoided in 75%
of the patients (19). A novel technique
called elastography has also been
proposed to help in the diagnosis of
fibrosis (142).
2.3.1.4. Prevalence
The prevalence of NAFLD varies
according the diagnostic criteria used. In
the Third National Health and Nutrition
Examination Survey (NHANES III)
carried out between 1988 and 1994 in
the US of 15676 adults, where excess
liver   was   defined   based  on   elevated
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Table 3. Obesity-independent markers of NASH.
Markers of NASH NASH/
NAFLD
/(Controls)*
Subjects
characteristics**
Liver fat
methodology
Reference
hs-CRP?, HOMA-IR? 69/16/(160) Age: 45 years
BMI: 26 kg/m2
Histology 413
Plasma cytokeratin-18 fragment? 21/8/(10) Age: 53/47/49 years
BMI: 33/31/27 kg/m2
Histology 456
fP-glucose?, fP-insulin?, IR
index?, HbA1c?, C-peptide ?, S-
ALT?, S-AST?, S-?GT?, fS-
triglycerides?, S-ferritin?
26/75/(4) Age: 44/40 years
BMI: 47/44 kg/m2
Histology 110
MCP1?, TNF?? 25/22 Age: 45/48 years
BMI: 32/29 kg/m2
Histology 175
fS-insulin?, C-peptide?, HOMA-
IR?, soluable TNF receptor 2?,
adiponectin?
80/29 Age: 51/42 years
BMI: 31/30 kg/m2
Histology 188
TPS? 48/48 Age: 42/43 years
BMI: 30/30 kg/m2
Histology 412
* Number of subjects
** Age and BMI denote mean values
aminotransferase concentrations, the
prevalence of NAFLD was 5.4% (75).
The real prevalence of NAFLD may be
at least 5-fold higher (~27%), given that
e.g. S-ALT are abnormally high in only
21% of subjects with NAFLD (52). In
the Dallas Heart Study, 33.6% of 2349
participants (age 18 to 65) had a fatty
liver determined by 1H-MRS than
equally obese Caucasian men (320). The
prevalences on NAFLD in subjects with
the metabolic syndrome and in patients
with type 2 diabetes are discussed below.
2.3.1.5. Natural history
The natural history of NAFLD remains
poorly characterized, since to date only a
few studies have addressed long-term
clinical course of the disease.
Histological change seems to be one
determinant of progression of NAFLD
(18). Patients with pure steatosis without
histological signs of inflammation have
the best prognosis (83). For example, a
Danish study of 109 predominantly
morbidly obese subjects followed for
nearly 17 years found the incidence of
cirrhosis to be less than 1% (88). It is
estimated that 12-20% of subjects with
simple steatosis develop NASH
characterized by mild (F1) or moderate
(F2) fibrosis (90). Patients with NASH
followed up from 4 to 9 years show 4-
16% progression rate to cirrhosis (121,
241, 331). Consequently, 100% of
patients with NASH and advanced
fibrosis have shown progression to
cirrhosis within 5-10 years (188, 360). A
recent Swedish study of 129 patients
with biopsy-verified NAFLD followed
up for approximately 14 years indicated
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that liver-related complications are the
third most common cause of death
among NAFLD patients (118). Obesity
and type 2 diabetes are more common in
patients with cirrhosis due to NAFLD
than in patients with cirrhosis due to
other causes (253). The prognosis of
cirrhosis  due  to  NASH  appears  to  be
better than in patients with cirrhosis due
to hepatitis C (189). NASH has been
predicted to become the number one of
orthoptic liver transplantation by the
year 2020 (68).
2.3.1.6. Associated conditions
2.3.1.6.1. The metabolic syndrome
Definition. The current definition of the
metabolic syndrome by the International
Diabetes Federation (IDF) includes waist
circumference over 94 cm in men and 80
cm in women, and at least two of the
following: increased fasting serum
glucose, triglycerides or blood pressure,
or a low HDL cholesterol concentration
(9). Previous metabolic syndrome
definition by the National Cholesterol
Education Program (NCEP) – Adult
Treatment Panel III (ATPIII) entails the
presence of three or more of these
components with higher cutpoints of
blood pressure and central obesity (122).
The first definition by WHO required the
presence of type 2 diabetes, impaired
glucose tolerance or insulin resistance
plus at least two of the following:
obesity determined by BMI or waist-to-
hip –ratio, dyslipidemia determined by
elevated serum triglycerides or a low
HDL cholesterol concentration, hyper-
tension, and microalbuminuria (10).
Prevalence. The prevalence of the
metabolic syndrome differs with respect
to study design, sample selection, the
definition of the metabolic syndrome,
and the age and gender of the population
studied (60). It has been estimated that
approximately 20-25% of populations
worldwide has the metabolic syndrome
defined by the ATP III criteria (60).
According to the IDF, a quarter of
world’s adults have the metabolic
syndrome (187).
Fat distribution, liver fat, and the
metabolic syndrome. Insulin resistance
and abnormal fat distribution are core
components of the metabolic syndrome
(8). Intra-abdominal and ectopic fat
accumulation (8), particularly in the liver
(462),  seem  to  increase  the  risk  of
developing the metabolic syndrome. For
example, a recent Japanese study
including 4401 employees without liver
disease or drug treatment (mean age 48
years, BMI 23 kg/m2), the odds ratios for
men  and  women  with  NAFLD  to
develop the metabolic syndrome (ATP
III criteria) during the follow-up of
approximately one year were 4.0 and
11.2 after adjustment for age, alcohol
intake, and changes in body weight
(170). Similar data on hepatic (171, 371)
and intra-abdominal (64, 287) fat
accumulation have been reported by
others. Other factors include insulin
resistance, physical inactivity, and aging
(8).
Risk of CVD, type 2 diabetes, and liver
disease. The metabolic syndrome
predicts an increased risk of both CVD
and type 2 diabetes more than the
individual components (8, 347, 487). For
example, in the San Antonio Heart Study
(n=2559, follow-up 7.4 years), the risk
of CVD was 1.7-fold and that of type 2
diabetes 5.8-fold increased in subjects
with as compared to those without the
metabolic syndrome, independent of age,
gender, ethnic origin, history of CVD
and type 2 diabetes, non-HDL
cholesterol, smoking, and family history
of CHD (255). Subjects with the
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Table 4. Prospective studies addressing liver enzymes as independent predictors of type 2
diabetes.
Cohort N Age (yrs)* BMI / body
weight*
Follow-up
(yrs)
Significant
predictor**
Reference
Swedesh men 766 54 24.8-27.4 kg/m2 13.5 S-ALT 302
Pima Indians 451 30 98 kg 6.9 S-ALT 443
WOSCOPS 5974 55-56 26.0-27.7 kg/m2 4.9 S-ALT 365
Mexico City
diabetes study
1441 46-52 27.7-28.6 kg/m2 7 S-AST 289
British Regional
Heart Study
7458 40-59 n.r. 12.8 S-?GT 314
D.E.S.I.R. 4201 47 23.9-25.3 kg/m2 3 S-?GT 15
Finnish men and
women
20158 25–64 42.4-46.2 kg/m2 12.7 S-?GT 240
CARDIA study 4844 18-30 23.3-26.2 kg/m2 5.5 and 15 S-?GT 239
IRAS 906 55 27.9-31.1 kg/m2 5.2 S-ALT and
S-AST
172
British Regional
Heart Study
3500 60-79 25.5-27.7 kg/m2 5 S-ALT and
S-?GT
447
Japanese men 6217 35-59 22.2-24.3 kg/m2 7 S-ALT, S-
AST, and S-
?GT
288
* Age and BMI or body weight denote mean values or mean ranges
**, Adjusted for body weight
metabolic syndrome have 3-4 -fold
higher risks of NASH and severe fibrosis
among NAFLD patients (269, 429) even
after adjustment for age, gender, and
BMI (269).
2.3.1.6.2. Type 2 diabetes
The studies in which the role of
steatosis, estimated measuring liver
enzymes, in the prediction of type 2
diabetes independent of body weight
have been evaluated, are listed in Table
4. Most recently, Sattar et al identified
three parameters which increased
gradually prior to type 2 diabetes: fasting
plasma glucose, S-ALT, and fS-
triglycerides (364). Importantly, there
were no changes in body weight prior to
the onset of type 2 diabetes (364). The
only epidemiological study of determin-
ing the prevalence of NAFLD in type 2
diabetic patients found 70% of the 2839
type 2 diabetic patients to have hepatic
steatosis (414), which is consistent with
previous estimates (18, 277). When
subjects with simple steatosis and those
with NASH have been compared,
hyperglycemia has been found to be
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significantly associated with NASH
(118, 176, 269) independent of age,
gender, and BMI (176, 269). Moreover,
type 2 diabetes and impaired glucose
tolerance are independent risk factors for
NASH (176) and the progression of
fibrosis (3, 118). A prospective study
indicated that type 2 diabetes or
impaired fasting glucose, age, and
baseline diagnosis of cirrhosis independ-
ently predict higher overall mortality
among patients with NAFLD (2).
2.3.1.6.3. CVD
In 1439 men and women aged 50-75
years participating in the Hoorn Study in
the  Netherlands,  increased  S-ALT  at
baseline increased the 10-year risk of
coronary heart disease events after
adjustment for components of the
metabolic syndrome and other CVD risk
factors (glucose tolerance status, systolic
blood pressure, HbA1c, LDL cholesterol,
and BMI) (369). Serum ?GT predicted
coronary events during a mean follow-up
of 15.7 years in 1878 men participating
in the MONICA/KORA study after
adjustment for traditional CVD risk
factors (278). Similarly, in a study of
2839 type 2 diabetic patients, NAFLD,
diagnosed by history and liver
ultrasound, was associated with an
increase in the risk of CVD even after
adjustment for components of the
metabolic syndrome (414). Ekstedt et al
found mortality from cardiovascular
causes to be significantly increased
(15.5% vs. 7.5%) among subjects with
NAFLD compared with a matched
reference-population (118).
2.3.1.6.4. Advanced liver disease
NAFLD can progress to cirrhosis, liver
failure, and hepatocellular carcinoma
(128). NASH is currently the most likely
cause of cryptogenic cirrhosis (59). The
risk of hepatocellular carcinoma tends to
be slightly higher in patients with
cryptogenic cirrhosis compared to those
with hepatitis C virus related cirrhosis
(343).
2.3.1.7. Factors regulating liver fat
content
Diet. Liver fat increases significantly in
response to a single mixed meal in
normal subjects (344). In cross-sectional
studies, a high liver fat content has been
related to increased dietary fat,
especially saturated fat intake (324, 423)
and a high glycemic index (436). Studies
examining effects of modulation of
dietary composition while maintaining
caloric intake constant on liver fat in
humans  are  few  and  of  small  size.
Westerbacka et al found that placing
overweight non-diabetic women on an
isocaloric diet containing 16% fat for 2
weeks decreased liver fat by 20%,
whereas a 2-week diet containing 56%
fat increased liver fat by 35% measured
by 1H-MRS (454). Four weeks of
fructose feeding (1.5 g fructose per kg
body weight) has been shown to induce
hypertriglyceridemia without changing
liver fat content measured by 1H-MRS
(238). Recently, an epidemiological
study of 349 subjects indicated that
subjects with NAFLD tend to consume
less fish rich in omega-3 fatty acids and
more meat and soft drinks than control
subjects independent of age, gender,
BMI, and total calorie intake (485).
Weight loss. Weight loss undoubtedly
and effectively reduces steatosis (259).
This decrease in liver fat is relatively
greater (79, 423) and occurs more
rapidly  (79)  than  fat  loss  from  other
compartments in the body. The impact of
weight loss on other changes, especially
fibrosis, is still unsettled (174, 433, 484).
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Physical training. In 30 middle-aged
men,  liver  fat  was  unrelated  to  VO2max
in a cross-sectional study (379). On the
other hand, in a cross-sectional analysis
of 191 apparently healthy individuals,
whose habitual physical activity was
assessed using a questionnaire, liver fat
content was lower in physically active
individuals, even after adjusting for age,
gender, and BMI (317). These cross-
sectional data do not, however, prove
cause  and  effect.  In  a  study  of  48
overweight subjects, liver fat, measured
using 1H-MRS, decreased by 0.97 units
by 10% weight loss achieved by diet
alone  (25%  calorie  restriction  for  6
months) and by 0.52 units by the
combination of diet (12.5% calorie
reduction) and exercise (12.5% increase
in energy expenditure) (235). The
decrease in liver fat was not different
between these groups (235), but the
study  was  not  powered  to  detect  a
difference. Thus, it is still unclear
whether exercise independent of weight
loss decreases liver fat content.
Table 5. Controlled studies in humans to treat fatty liver and/or NASH.
Intervention Diagnosis N Duration Change in
liver fat*
Reference
PPAR? AGONISTS
Rosiglitazone vs. placebo Type 2
diabetes
33 4 mos -45% (1H-
MRS)*
63
Rosiglitazone vs. metformin Type 2
diabetes
20 4 mos -51% (1H-
MRS)**
424
Rosiglitazone vs. placebo HAL 30 6 mos -15% (1H-
MRS)*
404
Pioglitazone vs. placebo NASH + IGT
or type 2
diabetes
55 6 mos -54% (1H-
MRS)*,
steatosis grade
? (BX)
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CYTOPROTECTIVE
AGENTS
UCDA vs. placebo NASH 166 2 yrs No change in
steatosis (BX)
252
COMBINATIONS
Vitamin E vs. vitamin E +
pioglitazone
NASH 20 6 mos Steatosis grade
? (BX) in both
groups
362
UCDA vs. UCDA + vitamin
E vs. placebo
NASH 48 2 yrs Steatosis grade
? (BX) by
UCDA +
vitamin E
117
* = % decrease in liver fat by determined by 1H-MRS or biopsy
** = % change in the PPAR? agonist group
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Drugs affecting liver fat content. Data on
controlled drug interventions in humans
are listed in Table 5. Of the agents
tested, PPAR? agonists consistently
decreased liver fat (21, 29, 63, 273, 424),
and in one study also inflammation,
ballooning necrosis, and possibly
fibrosis (29). These beneficial changes
were no longer seen 48 weeks after
discontinuation of treatment (257).
Regarding metformin, we found no
decrease in liver fat measured with 1H-
MRS in patients who were treatment
naive and did not loose weight (424). In
another study, liver fat measured
histologically decreases significantly by
approximately 50% in patients who also
lost 2 kg/m2 of BMI (56). It remains
unclear whether metformin decreases
liver fat independent of decreases in
body weight, as a 2.5 kg/m2 loss of BMI
decreases liver fat by 49% (423). A
number of randomized controlled trials
using metformin, glitazones, ACE
inhibitors, pentoxifylline, fenofibrate,
niacin, vitamin E, and PUFA are
currently being tested in NAFLD
(www.clinicaltrials.gov). In addition,
rimonabant, which has been shown to
decrease liver fat independent of body
fat in mice (148), and incretin mimetics
(108, 432) are studied in humans.
Genetic factors. A study in monozygotic
twins discordant for obesity by
Pietilainen et al showed that acquired
obesity increases liver fat content
independent of genetic background
(324). This does not, however, exclude a
role of genetic factors, but few data are
currently available. Polymorphisms of
the adiponectin receptor 1 promoter
region (396), usf-1 (209), and hepatic
lipase (397) have been linked to
variation in liver fat content, but in these
studies, which all are from the same
German cohort, liver fat content was
measured in only approximately 100
subjects. The -493 G/T promoter
polymorphism of the mitochondrial
triglyceride transfer protein (MTTP) has
been suggested to influence hepatic fat
accumulation measured by serum liver
enzyme concentrations and ultrasound
(33).
2.3.2. Skeletal muscle
2.3.2.1. Intra- and extramyocellular
lipid
Muscle lipid storage consists of
triglycerides within myocytes
(intramyocellular lipid, IMCL) and of
adipocytes located within the muscle
fibers (extramyocellular lipid, EMCL)
(260).
2.3.2.2. Quantification
Muscle biopsy. Lipid within the muscle
fibers can be directly visualized with
histochemical staining in light
microscopy, which reveals the
distribution of lipids within myocytes
(158, 323). Alternatively, biopsy
specimens can be analyzed using
electron microscopy (186). However, the
invasive nature of the biopsy and small
sample size (374) limit its use as a
method to quantitate IMCL.
1H-MRS. IMCL can be non-invasively
quantitated using 1H-MRS (260). The
geometrical arrangement of EMCL and
IMCL differs. EMCL is located in long
fatty septa along muscle fiber bundles or
fascia, whereas IMCL consists of lipid
droplets within the cytoplasm of muscle
cells (260). The resonances of lipids are
split in two methylene proton signals at
1.3 ppm for IMCL, and at 1.5 ppm for
EMCL (40, 368, 407). By quantitating
the areas under these methylene peaks
and  under  the  CH3-peak at 3.0 ppm
derived  from  total  creatine  (Cr), the %
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Figure 1. Skeletal muscle 1H-MRS spectra from tibialis anterior muscle of a subject with
intramyocellular fat percentage of 4.2.
IMCL can be calculated from the
following equation:
% IMCL = (area under the 1.3 ppm
methylene peak) / (area under the total
creatine peak + area under the 1.3 ppm
methylene peak) * 100%
2.3.2.3. Factors influencing IMCL
Obesity. Some studies have reported
positive associations between obesity
and IMCL content determined by light
microscopy (158, 323) or by 1H-MRS
(191). On the other hand, the majority of
studies in which IMCL has been
measured using 1H-MRS, no relationship
between these parameters has been
observed (198, 231, 316, 318, 440). In a
study group of 105 healthy non-diabetic
subjects, Thamer et al found intra-
myocellular lipid content in tibialis
anterior muscle to be positively associ-
ated with % whole body fat, and IMCL
content in soleus muscle with waist
circumference and waist-to-hip –ratio
(418). Weight loss has been shown to
decrease IMCL content in some (157,
158, 160, 161) but not all (363) studies.
Ethnicity. When different ethnic groups
have been compared, IMCL appeared
higher in South Asian than in European
men of the same BMI (141). Similarly,
Petersen  et  al  reported  IMCL  to  be
higher in Asian-Indian than in Caucasian
men (320). However, in the latter study,
the difference in IMCL between the
groups did not persist after adjusting for
age and BMI (320).
Diet. An increase in dietary fat intake
from 43% to 54% of total energy intake
for 4 weeks has been reported to increase
IMCL  by  57%  due  to  an  increase  in
muscle lipoprotein lipase activity (218).
Serum triglyceride or insulin con-
centrations did not change after the high-
fat diet in the latter study (218). Similar
results have recently been reported by
others (376, 398). A 4-week high
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fructose diet has been reported to
increased serum total and VLDL
triglyceride, lactate, glucose, and leptin
concentrations without changes in IMCL
(238).
Physical training
Acute regulation. Lipid droplets inside
myocytes are considered as an important
source of energy during exercise (437).
After a 45-120 minutes of acute exercise,
IMCL assessed by 1H-MRS decreases by
25-70% (51, 232, 236, 377). During
recovery, IMCL content has been shown
to return to baseline within 4 hours
(232). The rate of recovery dependents
on diet consumed after physical training:
IMCL content has been shown to be
significantly higher 22-24 hours
postexercise in subjects consuming high-
fat (60-70% of energy from fat) (392) or
moderate-fat (35% of energy from fat)
(236) than in those consuming very low-
fat (5-10% of energy from fat) (236,
392) recovery diets.
Long-term regulation. Endurance train-
ing increases IMCL content (120, 156,
190, 437). This phenomenon, known as
an ‘exercise paradox’ (156), is thought to
represent an adaptive response
increasing fuel availability during
exercise  (437).  The  increase  in  IMCL
seems to be driven by the exercise-
induced transcriptional reprogramming,
which enables greater IMCL use (372).
In a cross-sectional study of healthy non-
diabetic subjects, IMCL was positively
correlated with maximal aerobic power
(VO2max) in lean but not in obese
individuals (418).
2.3.2.4. Role of IMCL in skeletal
muscle insulin resistance
Insulin sensitivity in humans. IMCL
content is an important determinant of
insulin sensitivity in skeletal muscle
(260). A BMI-independent inverse
relationship between IMCL and insulin
sensitivity has been found in cross-
sectional studies including 20-26 non-
diabetic subjects (198, 231, 440). In
contrast, in a larger study of 105 non-
diabetic subjects, in which both obesity
and VO2max varied over a wide range,
no relationship between insulin
sensitivity and IMCL content was found
(418). Further analyses revealed that
insulin sensitivity was negatively related
to IMCL content only in subjects with
low aerobic power (418). On the other
hand, subjects with high aerobic power,
insulin sensitivity and IMCL content
were positively correlated (Fig. 2) (418).
Similar results have been obtained when
sedentary subjects and exercise-trained
individuals have been compared (156).
Thus, physical fitness appears to be an
important modifier of the relationship
between IMCL content and insulin
sensitivity. Lean, normoglycemic
insulin-resistant offspring of parents
with type 2 diabetes (28, 284) and
patients with type 2 diabetes (156, 246,
375, 410)  have either increased (28,
156, 246) or similar (284, 375, 410)
IMCL content compared to normo-
glycemic subjects matched for age,
gender, and BMI (156, 246, 284, 375,
410).
Molecular mechanisms
Studies in humans. IMCL accumulation
associates with defective insulin
signaling in human skeletal muscle
independent of obesity and physical
fitness (440). Both tyrosine phosphoryla-
tion of the insulin receptor and activation
of insulin receptor substrate-1 (IRS-1) –
associated phosphatidylinositol (PI) 3-
kinase, an important mediator of the
activation of glucose transport and
glycogen synthesis (115), are inversely
related to IMCL in non-diabetic subjects
(440). The mechanisms by which IMCL
may influence insulin signaling include
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Figure 2. Three-dimensional relationship between VO2max, IMCL in tibialis anterior
muscle, and insulin sensitivity. In untrained individuals, high IMCL predicts low insulin
sensitivity. In highly trained individuals, this relationship is reversed and high IMCL
predicts high insulin sensitivity. Adapted from  ref. 418 with permission.
increased intramyocellular concentra-
tions of long-chain acyl coenzyme-A
esters (119), which directly inhibit
hexokinase (421) and activate protein
kinase C (373), leading to decreased
tyrosine phosphorylation of IRS-1 (411).
Lessons from animal models. Several
animal models have been used to study
the role of IMCL in insulin resistance.
Rats fed with high-fat diet (300), mice
with muscle-specific overexpression of
lipoprotein lipase (219), and rats treated
with inhibitors of ?-oxidation (111)
exhibit increased IMCL content and
skeletal muscle insulin resistance.
Conversely, fatty acid translocase CD36
deficient mice display diminished IMCL
content and increased insulin sensitivity
(169). Although intramyocellular
triglycerides are inert and do not affect
insulin action in skeletal muscle (284,
403), they may give rise to metabolites
interfering with insulin signaling, such
as diacylglycerol, malonyl CoA, and
ceramides (180, 286, 384, 403).
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2.3.3. Other tissues
2.3.3.1. Pancreas
Zucker diabetic rats tend to accumulate
fat in pancreatic islet cells, resulting into
apoptosis and ?-cell dysfunction (242,
382). Treatment with PPAR? agonists
lowers islet fat content and preserves ?-
cell function in these animal models
(382). Studies in humans are rare
because of limitations in obtaining
pancreatic tissue (58). Recently, pancre-
atic fat has been quantitated using 1H-
MRS in humans (431) and appeared to
be ~50% higher in type 2 diabetic
patients  as  compared  to  age-  and  BMI-
matched non-diabetic subjects (431).
2.3.3.2. Heart
In transgenic mice, cardiac-specific
overexpression of long-chain acyl-CoA
synthetase (72) and fatty acid transport
protein 1 (71) result in triglyceride
accumulation, which in turn leads to
cardiac dysfunction and cardio-
myopathy. In humans, the myocardial
triglyceride content, assessed using 1H-
MRS (106, 408), has been shown to be
positively associated with BMI (408),
left ventricle mass (408), fasting serum
FFA concentrations (208), epicardial fat
(208), S-ALT concentrations (208),
hepatic triglyceride content measured by
1H-MRS (275), serum triglycerides
(275), HOMA-IR (275), and visceral fat
mass (275). Myocardial triglyceride
content has been found to be
approximately 2-fold higher in subjects
with impaired glucose tolerance and type
2 diabetes compared to subjects with
normal glucose tolerance in the face of
similar ejection fraction (275). In
patients with type 2 diabetes,
pioglitazone appears to decrease
myocardial triglyceride content without
changing either systolic or diastolic
blood pressure, or cardiac function
(486). Thus, the contribution of fat
accumulation in the heart to cardiac
dysfunction remains to be determined.
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3. AIMS OF THE STUDY
The present studies were undertaken to answer the following questions:
1) How are hepatic and intramyocellular fat accumulation related to hepatic and muscle
insulin resistance and features of the metabolic syndrome (I)?
2) What is the amount of liver fat in subjects with and without the metabolic syndrome,
and which clinically available markers best reflect liver fat content (II)?
3) How does liver fat accumulation influence insulin clearance (III)?
4) Do type 2 diabetic patients have more liver fat than age-, gender-, and BMI-matched
non-diabetic subjects, and how are liver enzymes (S-ALT, S-AST) related to liver fat in
type 2 diabetic patients and normal subjects (IV)?
5) How do type 2 diabetic patients using exceptionally high doses of insulin respond to
addition of a PPAR? agonist (V)?
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4. SUBJECTS AND STUDY DESIGNS
The study subjects were recruited based
on the following inclusion criteria: (i)
age 18 to 70 years; (ii) no known acute
or chronic disease based on history,
physical examination, ECG, and
standard laboratory tests (blood counts,
serum creatinine, thyroid-stimulating
hormone, electrolyte concentrations);
(iii) alcohol consumption less that 20g
per day; (iv) no evidence of hepatitis A,
B, or C, of autoimmune hepatitis, or
clinical signs or symptoms of inborn
errors of metabolism or history of use of
toxins or drugs known to induce
hepatitis. Elevated liver enzymes (S-
ALT,  S-AST,  and  S-?GT)  were  not
exclusion criteria. Aims and designs of
the studies are listed below. Written
informed consent was obtained from all
subjects. All protocols were approved by
the Ethics Committee of the Helsinki
University Central Hospital.
Study I
Aims: To examine the contribution of
hepatic and intramyocellular fat
accumulation to both hepatic and muscle
insulin resistance and to features of the
metabolic syndrome.
Subjects: Forty-five men were recruited
from occupational health services in
Helsinki.  Data on liver fat and hepatic
insulin sensitivity of 30 men have
previously been reported (379).
Measurements: The subjects were
studied on 4 separate occasions. All
measurements were performed within
one month. These measurements
included measurements of hepatic
insulin sensitivity (1st occasion), liver fat
and IMCL by 1H-MRS, and intra-
abdominal and subcutaneous fat by MRI
(2nd occasion), muscle insulin sensitivity
(3rd occasion), and maximal oxygen
consumption (VO2max, 4th occasion).
Study II
Aims: To determine the amount of liver
fat in subjects with and without the
metabolic syndrome, and to examine
which clinically available markers best
reflect liver fat content.
Subjects: A total of 271 non-diabetic
subjects were recruited primarily by
newspaper advertisements and by
contacting occupational health services.
A  total  of  20  subjects  were  receiving
medications for hypertension (Ca-
channel blockers or ACE-inhibitors), 6
subjects were receiving medications for
dyslipidemia (statins), and 7 subjects
were receiving medications for both
hypertension and dyslipidemia. 19 % of
the women were postmenopausal. If
eligible, the subjects were studied after
an overnight fast to assess body
composition and features of insulin
resistance. All except 75 subjects have
previously participated in metabolic
studies (324, 379, 425, 452).
Measurements: The study participants
underwent measurements of liver fat
content by 1H-MRS and body
composition by MRI. In addition,
components of the metabolic syndrome
as defined by IDF and features of insulin
resistance were measured.
Study III
Aims: To determine the effect of liver fat
on insulin clearance.
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Subjects: A  total  of  80  non-diabetic
subjects were recruited from the
occupational health services in Helsinki
and amongst those referred to the
Department of Gastroenterology because
of chronically elevated serum
transaminase concentrations. Data on
liver fat and hepatic insulin sensitivity of
30 men have previously been reported
(379). Baseline characteristics (but no
data on insulin sensitivity or clearance)
of these subjects were included in Study
II.
Measurements and design: The subjects
were divided into two groups based on
their median liver fat content (5.0%).
The study participants underwent
measurements of hepatic insulin
sensitivity and insulin clearance by
euglycemic hyperinsulinemic clamp
combined with the infusion of [3-
3H]glucose, and liver fat content by 1H-
MRS.
Study IV
Aims: To determine whether type 2
diabetic patients have more liver fat than
age-, gender-, and BMI-matched non-
diabetic subjects, and how liver enzymes
(S-ALT, S-AST) are related to liver fat
in type 2 diabetic and normal subjects.
Subjects: A  total  of  70  non-diabetic
subjects and 70 type 2 diabetic patients
were recruited by newspaper advertise-
ments and by contacting occupational
health services in Helsinki. Exclusion
criteria included proliferative
retinopathy and use of antihypertensives
possibly influencing glucose metabolism
??-blockers and thiazides), or of
thiazolidinediones. A total of 13 non-
diabetic subjects and 32 type 2 diabetic
patients received antihypertensive
medications (ACE-inhibitors or Ca-
channel blockers). A total of 31 type 2
diabetic patients were treated with diet
alone, 17 with metformin, and 22 with a
combination of metformin and insulin.
Five non-diabetic subjects and 22 type 2
diabetic patients were receiving statins.
Regarding the insulin-treated patients,
additional inclusion criteria included
stable body weight and insulin dose for
at least 6 months. Data on non-diabetic
subjects  (Study II)  and 46 of  the type 2
diabetic patients participating in
treatment studies (204, 355, 424) have
previously been reported. For the latter
patients, only baseline data are included.
Measurements: The study participants
underwent measurements of liver fat
content by 1H-MRS and body
composition by MRI. In addition,
circulating markers of insulin resistance
and serum liver enzyme concentrations
were determined.
Study V
Aims: To examine how type 2 diabetic
patients using exceptionally high doses
of insulin respond to addition of a
PPAR? agonist.
Subjects: This study was an investigator-
initiated study not financially supported
by the industry. We recruited, by
contacting specialists in Southern
Finland, 14 patients (9 men and 5
women, mean duration of diabetes 12
years) with type 2 diabetes who were
poorly controlled despite high-dose
insulin therapy (>100 IU/day, range 115-
400 IU/day) combined with metformin
(2  g/day  for  over  2  years)  to be treated
with additional rosiglitazone (8 mg once
a day) for 8 months. The insulin
treatment regiments varied from basal
insulin alone (n=5) to use of multiple
insulin injection therapy (n=9). The
patients were instructed to decrease their
insulin doses by 4-10 IU whenever
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hypoglycemia (fasting plasma glucose <
4 mmol/l) occurred. Additional inclusion
criteria were stable insulin dose for at
least 2 years, and body weight and
glycemic  control  for  at  least  6  months
prior to participation. Exclusion criteria
were clinical or echocardiographic
evidence of heart failure, other
cardiovascular disease, or any other
significant disease that would make
implementation of the study protocol
impossible, treatment with drugs that
may alter glucose metabolism (steroids,
?-blockers and thiazide diuretics),
abnormal serum creatinine, macro-
albuminuria, and drug abuse. The
inclusion and exclusion criteria were
reviewed at a screening visit, where the
patients underwent a history and
physical examination, and blood samples
were taken for measurement of the blood
count, serum creatinine, electrolytes,
fasting plasma glucose, HbA1c, liver
enzymes, and lipids. An ECG was
recorded, and a urine sample was taken
to exclude patients with infections and
macroalbuminuria. Transthoracic echo-
cardiography was performed using Vivid
7 digital ultrasonography system (GE
Vingmed Ultrasound, Horton, Norway).
The left ventricular ejection fraction was
calculated by M-mode echocardiography
from the parasternal long-axis view.
Measurements  were  made  while  the
subject was lying in the left lateral
recumbent position from three consecu-
tive beats. The average of three beats
was used for analysis. Subjects with left
ventricular ejection fraction less than
50% were excluded.
Measurement and design: If a patient
was considered eligible after the
screening visit, metabolic studies
(measurement of liver fat, insulin
sensitivity  of  the  glucose  Ra and  Rd,
body composition, and substrate oxida-
tion rates) were performed before and
after 8 months of additional treatment
with rosiglitazone.
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5. METHODS
5.1. Hepatic insulin sensitivity (Studies
I, III, and V)
In Studies I and III, two indwelling
catheters were placed at 8 a.m. after an
overnight fast in an antecubital vein and
retrogradely in a heated hand vein for
infusion of glucose, insulin, and [3-
3H]glucose and for sampling of
arterialized venous blood. In order to
determine Ra under basal and
hyperinsulinemic conditions, [3-
3H]glucose was infused in a primed (20
µCi) continuous (0.2 µCi/min) fashion
for a total of 360 min (104, 355).
Baseline blood samples were taken for
measurement of fS-insulin and fP-
glucose concentrations and for the
biochemical measurements (S-ALT, S-
ALT, fS-triglycerides, fS-HDL
concentrations, fS-C-peptide, fS-
adiponectin, and fS-FFA). After 120
min, insulin was infused in a primed
continuous (0.3 mU/kg·min) fashion as
previously described (355). Plasma
glucose was maintained at 5 mmol/liter
(90 mg/dl) until 360 min using a variable
rate infusion of 20% glucose (104).
Blood samples for measurement of
glucose specific activity and FFA
concentrations were taken at 90, 100,
110, and 120 min and at 15- to 30-min
intervals between 120 and 360 min.
Serum free insulin concentrations were
measured at 0, 120, 150, 180, and at 60
min intervals between 240 and 360 min.
In Study V, patients were admitted to the
hospital on the evening before the study.
At 6 p.m., an indwelling 18-gauge
catheter (Venflon, Viggo-Spectramed,
Helsingborg, Sweden) equipped with an
obturator was inserted in an antecubital
vein. On this evening before the study,
the patients did not take their bedtime
insulin injection. To determine glucose
Ra and  Rd, a primed continuous
intravenous infusion of [3-3H]glucose
was started at 4 a.m. and continued for a
total of 11 h. The priming dose of [3-
3H]glucose was adjusted according to the
fasting blood glucose concentration
measured at 4 a.m. as follows: priming
dose = [glucose (mmol/l) at 4 a.m./5] x
20 µCi/min. This dose was infused
intravenously over 10 min and was
followed by a continuous-rate infusion
of [3-3H]glucose at a rate of 0.2 µCi/min
as previously described (355). Before
start of the insulin infusion, another
catheter was inserted in a retrograde
position in a heated dorsal hand vein for
withdrawal of arterialized venous blood.
Baseline blood samples were taken for
measurement of fasting plasma glucose;
glucose SA; HbA1c; triglycerides; total,
HDL, and LDL cholesterol; FFA; and
serum free insulin concentrations. At 9
a.m., after a 300-min equilibrium period,
a primed continuous (0.3 mU/kg·min)
infusion of insulin (Actrapid Human,
Novo Nordisk, Bagsvaerd, Denmark)
was  started  (0  min), as previously
described (104). Plasma glucose was
adjusted to and then maintained at 8
mmol/l (144 mg/dl) for 360 min. This
was done using a variable-rate infusion
of 20% glucose based on plasma glucose
measurements, which were made from
arterialized venous blood every 5–10
min. Blood samples for measurement of
glucose  SA were  taken  basally  at -30, -
20, and 0 min, and at 120, 180, 240, 280,
300, 330, and 360 min during the insulin
infusion. Serum free insulin
concentrations were measured every 60
min.
Glucose specific activity was determined
as previously described (336). Glucose
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Ra and  Rd were calculated using the
Steele equation, assuming a pool fraction
of 0.65 for glucose and distribution
volume of 200 ml/kg for glucose.
Hepatic glucose Ra was calculated by
subtracting the exogenous glucose
infusion rate required to maintain
euglycemia during hyperinsulinemia
(120-360 min in Studies I and III; 0–360
min in Study V) from the rate of total
glucose Ra. The percent suppression of
basal hepatic glucose Ra by insulin was
used  as  a  measure  of  hepatic  insulin
sensitivity, i.e., the sensitivity of hepatic
glucose production to insulin (%
suppression of hepatic Ra).
5.2. Muscle insulin sensitivity (Study I)
The study was started at 8 a.m. after a
12-hour  fast.  Two 18-gauge catheters
(Venflon; Viggo-Spectramed, Helsing-
borg, Sweden) were inserted, one in the
left antecubital vein for infusions of
insulin and glucose and another
retrogradely in a ipsilateral heated dorsal
hand vein for withdrawal of arterialized
venous blood. Insulin (Actrapid Human;
Novo Nordisk, Copenhagen, Denmark)
was infused in a primed-continuous
manner at a rate of 1 mU/kg·min for 120
minutes. Normoglycaemia was main-
tained by adjusting the rate of a 20%
glucose infusion based on plasma
glucose measurements, which were
performed every 5 minutes from
arterialized venous blood. Blood
samples  for  serum  free  insulin  con-
centrations were withdrawn every 30
minutes during the 2-hour insulin
infusion. The  M-value  (0-120  min)  was
calculated from the glucose infusion rate
after correction for changes in the
glucose pool size and expressed per fat
free mass (FFM).
5.3. Insulin clearance (Studies III and
V)
Insulin clearance measured directly
using the low-dose (0.3 mU/kg·min)
insulin infusion clamp tecnique (see
5.1.). In Study III, insulin clearance was
calculated by dividing the rate of insulin
infusion (mU/kgFFM·min) by the
steady-state serum insulin concentration
measured between 150 and 360 min
(203). Increment in serum insulin was
calculated by subtracting fasting serum
insulin concentration from the steady-
state serum insulin concentration (150 to
360 min). In Study V, insulin clearance
(ml/kgFFM·min) was calculated by
dividing the rate of insulin infusion
(mU/kgFFM·min) by the increment in
serum insulin concentration (mean
concentration measured during the
insulin infusion minus fasting serum
insulin).
5.4. Liver fat content
Histological determination (Study III). A
liver biopsy was taken in 13 patients
with suspected non-alcoholic steatosis
under ultrasound control. Fat content of
the  liver  biopsy  specimens  (%  fat  of
surface area in light microscope) was
analysed by an experienced liver
pathologist in a blinded fashion.
1H-MRS (Studies I, II, III, IV, and V).
Localised single voxel (2×2×2 cm3)
proton spectra were acquired using a 1.5-
T whole-body system (Siemens
Magnetom Vision, Erlangen, Germany),
which consisted of a combination of
whole-body and loop surface coils for
radiofrequency transmitting and signal
receiving, as previously described (355).
T1-weighted high-resolution MRI scans
were used for localisation of the voxel of
interest within the right lobe of the liver.
Magnetic resonance spectroscopy
measurements of the liver fat were
performed in the middle of the right lobe
of  the  liver  at  a  location  that  was
individually determined for each subject;
vascular structures and subcutaneous fat
tissue were avoided when selecting the
voxel. Subjects lay on their stomachs on
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the surface coil, which was embedded in
a mattress in order to minimise
abdominal movement due to breathing.
The single voxel spectra were recorded
using the stimulated-echo acquisition
mode sequence, with an echo time of
20 ms, a repetition time of 3000 ms, a
mixing time of 30 ms, 1024 data points
over 1000 kHz spectral width with 32
averages. Water-suppressed spectra with
128  averages  were  also  recorded  to
detect weak lipid signals. A short echo
time and long repetition time was chosen
to ensure a fully relaxed water signal,
which was used as an internal standard.
Chemical shifts were measured relative
to water at 4.80 ppm. The methylene
signal, which represents intracellular
triglyceride, was measured at 1.4 ppm.
Signal intensities were quantified by
using an analysis program, VAPRO-
MRUI (http://www.mrui.uab.es/mrui/).
Spectroscopic intracellular triglyceride
content (liver fat) was expressed as a
ratio of the area under the methylene
peak to that under the methylene and
water peaks (? 100 = liver fat %). This
measurement has been validated against
histologically determined lipid content
(422) and against estimates of fatty
degeneration or infiltration by X-ray
computer-assisted tomography (355). All
spectra were analysed by physicists who
were unaware of any of the clinical data.
The reproducibility of repeated
measurements of liver fat in non-diabetic
subjects studied on two separate
occasions by the same reader in our
laboratory is 11% (405).
5.5. IMCL (Study I)
Magnetic resonance images for
localization and 1H-MRS were acquired
using a 1.5 T MR system (Magnetom
Vision; Siemens, Erlangen, Germany) as
previously described (440). A loop
surface coil was used for detection. The
subjects lay supine, with the left leg
immobilized by firm padding. One-third
of the distance from the trochanter major
of the femur to the middle of the patella
was measured, and the center of the coil
was placed in contact with that spot. The
1H-spectra were obtained from
quadriceps femoris (vastus lateralis)
muscle. The volume of interest, voxel
(13 × 13 × 20 mm3), was placed inside
the lateral part of the vastus lateralis
muscle to ensure parallel fiber
orientation. The position of the voxel
was chosen on the T1-weighted MR
images so that it did not contain any
visible fat or fasciae known to contain
significant amounts of adipocytes (40),
which would affect the resonance-
frequency shift data. Spatial localization
was achieved by using a stimulated echo
acquisition mode applied with a
repetition time of 3,000 ms, with an echo
time of 20 ms, and a mixing time of 30
ms. We used 128 excitations with water
presaturation. The resonance at 1.5 ppm
originates from the extramyocellular
CH2-protons of lipids (triglycerides and
fatty acids) and the resonance at 1.3 ppm
from intramyocellular CH2-protons of
lipids (40, 368, 407). Resonance
intensities were related to resonance at
3.0 ppm, which is derived from the CH3-
protons of total creatine (creatine and
phosphocreatine). IMCL was expressed
as  a  ratio  of  the  area  under  the
intramyocellular methylene peak to that
under the methylene and total creatine
peaks (? 100 = IMCL %). The spectral
data were fitted in time domain with the
program MRUI, based on the solving of
nonlinear least squares problems (368).
5.6. Measurements of body
composition (Studies I, II, III, IV, and
V)
Intra-abdominal and abdominal
subcutaneous fat volumes. A series of 16
T1-weighted trans-axial scans were
acquired from a region extending from 8
cm above to 8 cm below the 4th and 5th
42
lumbar interspace (16 slices, field of
view 375×500 mm2, slice thickness
10 mm, breath-hold repetition time
138.9 ms, echo time 4.1 ms). Intra-
abdominal and subcutaneous fat areas
were measured using an image analysis
program (Alice 3.0, Parexel, Waltham,
MA). A histogram of pixel intensity in
the intra-abdominal region was
displayed, and the intensity correspond-
ing to the nadir between the lean and fat
peaks was used as a cut-off point. Intra-
abdominal adipose tissue was defined as
the area of pixels in the intra-abdominal
region  above  this  cut-off  point.  For
calculation of subcutaneous adipose
tissue area, a region of interest was first
manually drawn at the demarcation of
subcutaneous adipose tissue and intra-
abdominal adipose tissue, as previously
described (355).
Whole body fat %. The % body fat was
determined using bioelectrical imped-
ance analysis (BioElectrical Impedance
Analyzer System, model number BIA-
101A, RJL Systems, Detroit, MI) (256).
Waist-to-hip –ratio. Waist circumfer-
ence was measured midway between
spina  iliaca  superior  and  the  lower  rib
margin, and hip circumference at the
level of the greater trochanters (270).
5.7. Maximal aerobic power (VO2max)
(Study I)
Maximal aerobic power was measured
directly using an incremental work-
conducted upright exercise test with an
electrically braked cycle ergometer
(Ergometer Ergoline 900ERG, Ergoline
GmbH, Bitz, Germany) combined with
continuous analysis of expiratory gases
and minute ventilation (Vmax229 series,
SensorMedics, Yorba Linda, CA).
Exercise was started at a work load of 50
watts. The work load was then increased
by 50 watts every 3 min until perceived
exhaustion or a respiratory quotient of
1.10 was reached. Maximal aerobic
power  was  defined  as  the  VO2max
during the last 30 sec of exercise.
5.8. Substrate oxidation rates (Study
V)
Glucose and lipid oxidation rates were
measured with indirect calorimetry using
the Deltatrac Metabolic Monitor (Datex,
Helsinki, Finland) as previously
described (130, 476). The measurements
were performed for 40 min during the
basal period and the last hour of insulin
clamp. Samples of inspired and expired
air, which were suctioned at 40 l/min,
were  analyzed  for  O2 and CO2
concentration differences using
paramagnetic O2 and  CO2 analyzers,
respectively. The hood was placed on the
subject's head 10 min before the
measurement was started. Urine was
collected during the study, and the
protein oxidation rate was estimated
from urea nitrogen excretion (1 g
nitrogen = 6.25 g protein). The following
constants were used for calculation of
glucose and lipid oxidation rates from
gas exchange data: oxidation of 1 g of
protein requires 966 ml of O2 and
produces 782 ml of CO2, of 1 g of
glucose requires 746 ml  of  O2 and
produces 746 ml of CO2, and of 1 g of
lipid requires 2,029 ml of O2 and
produces 1,430 ml of CO2. Energy
production rates (J/kgFFM·min) were
calculated assuming oxidation of 1 mg
carbohydrate produces 15.65 J; 1 mg
lipid, 39.75 J; and 1 mg protein, 17.15 J
(130).
5.9. Diagnosis of the metabolic
syndrome (Studies I and II)
The metabolic syndrome was defined
according to criteria of the International
Diabetes Federation (9): central obesity
(waist circumference ?94 cm in men and
?80 cm in women) and at least two of
the following factors: 1) fS-triglycerides
?1.70 mmol/l or specific treatment for
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this lipid abnormality; 2) fS-HDL
cholesterol <1.03 mmol/l in men and
<1.29 mmol/l in women or specific
treatment for this lipid abnormality; 3)
systolic BP ?130 mmHg or diastolic BP
?85 mmHg or treatment for previously
diagnosed hypertension; 4) fP-glucose
?5.6 mmol/l or previously diagnosed
type 2 diabetes.
5.10. Analytical procedures
Plasma glucose concentrations were
measured in duplicate with the glucose
oxidase method using Beckman Glucose
Analyzer II (Beckman Instruments,
Fullerton, CA) (Studies I, II, III, IV, and
V)  (205).  Serum  free  insulin
concentrations were measured with the
Auto-DELFIA kit (Wallac, Turku,
Finland) (Studies I, II, III, IV, and V),
and C-peptide concentrations by
radioimmunoassay (233) (Studies I, II,
III, and IV). FS-HDL cholesterol and fS-
triglyceride concentrations were
measured with the enzymatic kits from
Roche Diagnostics using an autoanalyser
(Roche Diagnostics Hitachi, Hitachi
Ltd., Tokyo, Japan) (Studies I, II, III, IV,
and V). The concentrations of LDL
cholesterol were calculated using the
Friedewald formula (144) (Studies II,
IV, and V). S-ALT and S-AST activities
were determined as recommended by the
European Committee for Clinical
Laboratory Standards (Studies I, II, III,
IV, and V). Serum adiponectin
concentrations were measured by an
ELISA kit from B-Bridge International
(San Jose, CA) (Study I), and serum FFA
concentrations were measured using a
fluorometric method (280) (Studies I, II,
III, IV, and V). In order to determine
glucose SA, plasma was deproteinized
with Ba(OH)2 and ZnSO4 and evaporated
as described (336) (Studies I, III, and V).
5.11. Statistical analyses (Studies I, II,
III, IV, and V)
In all studies, a p-value of less than 0.05
was considered statistically significant.
Calculations were made using GraphPad
Prism version 4.00 for Windows
(GraphPad Software, San Diego, CA)
(Studies  I,  II,  III,  IV,  and  V),  SysStat
Statistical Package (SysStat version 10;
SysStat, Evanston, IL) (Studies I and II),
and SPSS 11.0 (Studies I and II) or 14.0
(Studies III, IV, and V) for Windows
(SPSS, Chicago, IL).
Study I. The subjects were divided into
two equally-sized groups based on their
median IMCL (9.0%) or liver fat content
(3.0%). Non-normally distributed data
were used after logarithmic (base 10)
transformation. If distributed normally,
data  are  shown  as  means  ±  SEM,
whereas non-normally distributed data
are shown as median (25% percentile,
75% percentile). The unpaired Student’s
t test was used to compare mean values
between groups. Analysis of covariance
was used to adjust for body mass index,
% body fat, liver fat (LFAT), and IMCL.
Correlation analyses were performed
using Spearman’s nonparametric rank
correlation coefficient. Multiple linear
regression analysis was used to analyse
independent determinants of liver fat
content and muscle insulin sensitivity.
Study II. Non-normally distributed data
were used after logarithmic
transformation. If distributed normally,
data are shown as means ± SD, whereas
non-normally distributed data are shown
as median (25% percentile, 75%
percentile). The unpaired Student s t test
was used to compare mean values
between  men  and  women.  Analysis  of
covariance was used to compare slopes
and intercepts of regression lines for
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men and women. If neither the slopes
nor the intercepts differed between
women and men, a common regression
equation was calculated for all data.
Analysis of covariance was used to
adjust for age, gender and body mass
index.
Study III. Non-normally distributed data
were used after logarithmic
transformation. The unpaired Student s t
test was used to compare mean values
between groups. Analysis of covariance
was used to adjust for age, gender, and
BMI. Correlation analyses were
performed using Spearman’s
nonparametric rank correlation
coefficient. Analysis of covariance was
used to compare slopes of regression
lines between liver fat and fS-insulin and
fS-insulin adjusted for insulin clearance.
If neither the slopes nor the intercepts
differed between women and men, a
common regression equation was
calculated for all data. Multiple linear
regression analyses were used to
determine the independent determinants
of the variation in fS-insulin
concentrations. For calculation of the %
variation in fasting insulin
concentrations attributed to impaired
insulin clearance due to liver fat, the
difference between the % derived from
the multiple regression analyses (insulin
clearance and liver fat content) and the
%  derived  from  simple  regression
analyses  of  one  of  the  variables  (e.g.
insulin clearance) was subtracted from
the % derived from simple regression
analyses of the other variable (e.g. liver
fat).
Study IV. Non-normally distributed data
were used after logarithmic
transformation. If distributed normally,
data  are  shown  as  mean  ±  SEM,  while
non-normally distributed data are shown
as median followed by the interquartile
range (25th and 75th percentiles). The
unpaired Student s t test was used to
compare mean values between the
groups. Analysis of covariance was used
to compare slopes and intercepts of
regression lines for the non-diabetic
subjects and the type 2 diabetic patients,
and for comparison of liver fat in the
type 2 diabetic patients treated with diet,
metformin or with insulin-metformin
combination therapy. If neither the
slopes nor the intercepts differed
between the groups, a common
regression equation was calculated.
Correlation analyses were performed
using Spearman’s nonparametric rank
correlation coefficient. Analysis of
covariance was used to adjust for intra-
abdominal fat content.
Study V. The paired t-test was used to
compare changes before and after
additional rosiglitazone treatment.
Logarithmic transformation was
performed if necessary. Correlation
analyses were performed using the
Spearman nonparametric correlation
coefficient.
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6. RESULTS
6.1. Tissue specificity of insulin
resistance (Study I)
Characteristics of the study groups. The
high  and  the  low  LFAT  groups  were
similar with respect to age. The high
LFAT group was more obese than the
low LFAT group, but the groups did not
differ with respect to IMCL (Fig. 3). FS-
insulin and liver enzymes were
significantly  higher  and  fS-adiponectin
significantly lower in the high than the
low LFAT group (Table 6 and Fig. 3).
The differences in fS-insulin (p<0.0001)
and S-ALT (p<0.0001) and S-AST
(p=0.001) remained significant after
adjusting for BMI. FS-adiponectin
concentrations did not differ
significantly after adjusting for % body
fat (p=0.09).
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Figure 3. Bar graphs show LFAT (a), IMCL (b), fS-insulin (c), and fS-adiponectin (d) in
the low and high liver fat groups. *, p?0.05; ***, p<0.0001 for the low vs. high LFAT
groups.
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Table 6. Subject characteristics in Study I.
Low LFAT High LFAT Low IMCL High IMCL
N 23 22 23 22
Age (y) 43±2 41±2 42±2 43±2
Body composition
BMI (kg/m2) 24.7±0.6 27.7±0.9* 24.7±0.7 27.7±0.8**
Waist (cm) 91±2 99±2* 91±2 99±2**
% fat 18.6±1.0 22.6±1.0* 18.8±1.1 22.4±1.0*
IA fat (cm3) 1100 (650-1320) 1630 (930-2430)* 1010 (680-1320) 1780 (1180-2600)**
SC fat (cm3) 2080 (1470-2910) 2600 (1990-3370) 2000 (1370-2860) 2490 (2010-3110)
Liver fat (%) 2.0 (1.0-2.0) 12.0 (5.7-18.5)*** 2.5 (2.0-6.0) 5.3 (1.7-17.5)
IMCL (%) 7.5 (3.0-16.2) 15.5 (5.0-23.5) 5.0 (2.3-7.5) 19.5 (16.0-26.0)***
Components of the
MS
fP-glucose (mmol/l) 5.5±0.09 5.7±0.09 5.5±0.09 5.6±0.12
S-triglycerides
(mmol/l)
1.0±0.08 1.6±0.2** 1.12±0.09 1.50±0.22
S-HDL cholesterol
(mmol/l)
1.48±0.07 1.26±0.06* 1.38±0.06 1.36±0.08
Systolic BP (mmHg) 130±3 133±3 128±3 136±4
Diastolic BP (mmHg) 85±2 87±3 83±2 89±2
Other parameters
fS-insulin (mU/l) 5.3±0.4 9.2±0.7*** 6.5±0.5 8.0±0.8
fS-adiponectin
??g/ml)
12.2±1.2 9.5±1.2* 11.4±0.9 10.3±1.0
fS-FFA (?mol/l) 556±39 647±45 551±33 643±49
S-ALT (U/l) 26±2 48±4*** 31±3 43±5
S-AST (U/l) 26±2 35±2*** 28±2 33±3
M-value (mg/kg
FFM·min)
6.26±0.39 4.18±0.38*** 5.73±0.43 4.73±0.43
VO2max
(ml/kg FFM·min)
45.2±1.2 41.1±1.4* 44.3±1.4 42.0±1.3
Data are shown as mean ± SEM or median (25% percentile, 75% percentile). *, p?0.05;
**, p<0.01; ***, p<0.0001 for low vs. high LFAT groups or low vs. high IMCL groups.
The low and high IMCL groups were
similar with respect to age, but the high
IMCL group was more obese than the
low  IMCL  group  (Table  6).  LFAT  was
comparable between the groups, as were
fS-insulin and fS-adiponectin con-
centrations (Fig. 4). BMI was similar
between  the  low  LFAT  and  low  IMCL
groups, and the high LFAT and high
IMCL groups  (Table  6).  IMCL was  not
correlated with liver fat content (r=0.16,
NS).
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Figure  4.  IMCL  (a),  liver  fat  (b), fS-insulin (c), and fS-adiponectin (d) in the low and
high IMCL groups. ***, p<0.0001 for the low vs. high IMCL groups.
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Components of the metabolic syndrome.
In the high LFAT group, S-triglycerides
were higher and S-HDL cholesterol
concentrations lower as compared to the
low LFAT group (Table 6). The groups
were  comparable  with  respect  to  fP-
glucose and systolic and diastolic blood
pressure. These results remained
unchanged if adjusted for IMCL. There
was no significant difference in any
component of the metabolic syndrome
between the high and low IMCL groups
(Table 6) even after adjusting for liver
fat content. In subjects with the
metabolic syndrome (n=14), LFAT was
significantly higher (10.5% [3.0-18.0%])
than in those without the syndrome
(n=31, 2.0% [1.5-6.0%], p=0.017) even
independent of BMI (p<0.05) and IMCL
(p=0.003), whereas IMCL was
comparable between the subjects with
and without the metabolic syndrome
(Fig. 5) even if adjusted for liver fat.
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Figure 5. Liver  fat  (a)  and  IMCL  (b) in subjects without and with the metabolic
syndrome. **, p<0.01.
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Hepatic and muscle insulin sensitivity.
Rates of basal hepatic glucose Ra were
comparable between the high and the
low LFAT groups (2.63±0.13 and
2.41±0.10 mg/kg FFM·min, respectively,
NS). Serum insulin concentrations
during the insulin infusion (150-360
min) averaged 19±1 and 25±1 mU/l in
the high and low LFAT group
(p<0.0001). During the last hour of the
insulin infusion, the % suppression of
hepatic glucose production was inversely
related to liver fat content (r=-0.30,
p<0.05, Fig. 6), and averaged 79% (51-
120%) vs. 97 % (75-129%) (high vs. low
LFAT group, p<0.05). Muscle insulin
sensitivity (M-value) was significantly
lower in the high (4.18±0.38 mg/kg
FFM·min) than in the low (6.26±0.39
mg/kg FFM·min, p=0.0008) LFAT
group. In multiple linear regression
analysis, BMI (p=0.016) but not
VO2max (p=0.19) independently
explained variation in LFAT, and
together explained 21% of its variation
(p=0.007 for ANOVA).
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Figure 6. The relationship between % suppression of hepatic glucose production during
the last hour of hyperinsulinemia (300-360 min) and liver fat content. r=-0.30, p<0.05.
The low and high IMCL groups were
comparable with respect to basal hepatic
glucose Ra in the basal state (2.61±0.12
vs. 2.54±0.11 mg/kg FFM·min,
respectively, NS). Serum insulin concen-
trations during the insulin infusion (23±1
vs. 21±1 mU/l, NS) and the %
suppression (96% (64-145%) vs. 84%
(56-109%), NS) did not differ signifi-
cantly between the IMCL groups, nor
did muscle insulin sensitivity (4.73±0.43
vs. 5.73±0.43 mg/kg FFM·min, high vs.
low IMCL group, NS).
In simple linear regression analysis,
muscle insulin sensitivity was inversely
related to BMI (r=-0.57, p<0.0001; r=-
0.50, p<0.0001 if adjusted for LFAT)
and positively related to VO2max
(r=0.41, p=0.005; r=-0.18, NS if
adjusted for LFAT, Fig. 7). In multiple
linear  regression  analysis,  BMI
(p<0.0001) and VO2max (p<0.05) were
independent determinants of muscle
insulin sensitivity and together explained
46.7% of is variation (p<0.0001 for
ANOVA).
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Figure  7. The relationships between (a) BMI and IMCL; (b) M-value and IMCL; (c)
VO2max and IMCL; (d) M-value and VO2max;  (e)  BMI  and  VO2max;  (f) M-value and
BMI; and (g) M-value and liver fat content.
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If  LFAT  was  incorporated  into  these
analyses, BMI (p<0.0001) and LFAT
(p=0.035) but not VO2max (p=0.12)
were independent determinants of
muscle insulin sensitivity (r2=52%,
p<0.0001 for ANOVA). IMCL
correlated significantly with BMI
(r=0.47, p=0.001, r=0.35, p=0.018 after
adjusting for LFAT) but was not related
to VO2max (r=-0.09, NS; r=-0.05, NS
adjusted for LFAT) or muscle insulin
sensitivity  (r=-0.18,  NS;  r=-0.11,  NS
adjusted for LFAT, Fig. 7).
S-FFA concentrations during prolonged
low-dose insulin infusion. In the LFAT
groups, fS-FFA concentrations were
comparable in the basal state, but after
30 minutes of the 0.3 mU/kg·min insulin
infusion, S-FFA concentrations were
significantly higher in the high as
compared  to  the  low  LFAT  group
(459±30 ?mol/l vs. 354±25 ?mol/l,
respectively, p=0.009). During the next
3.5 hours of insulin infusion, S-FFA
remained significantly higher in the high
than in the low LFAT group (Fig. 8).
The difference in mean S-FFA remained
significant after adjusting for age and
BMI (p=0.03). In the IMCL groups, fS-
FFA concentrations were similar basally
and during the two first hours of insulin
infusion. During the last hour, S-FFA
concentrations were significantly higher
in the high IMCL group (Fig. 8), but
after adjusting for BMI, these
differences did not remain significant.
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Figure 8. Serum FFA concentrations during the low-dose insulin infusion (120-360 min)
in the high and low LFAT groups (a) and the high and low IMCL groups (b). The FFA
concentrations were compared using analysis of variance for repeated measures followed
the Tukey’s HSD test for pairwise comparisons.*, p?0.05; **, p<0.01; ***, p<0.001.
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6.2. Liver fat in the metabolic
syndrome (Study II)
Characteristics of the women and men
(Table 7). The women and men were
similar with respect to age and absolute
body weight. Women had higher BMI,
waist circumference, waist-to-hip –ratio,
% total body and subcutaneous fat
volume than men, but intra-abdominal
and liver fat were similar in both groups.
Table 7. Basic characteristics in Study II.
Women Men p-value
n 162 109
Age (y) 38±12 37±11 NS
Body composition
Weight (kg) 86.0±6.4 86.1±6.7 NS
BMI (kg/m2) 31.4±6.8 26.9±4.9 0.0001
Waist (cm) 101±16 96±14 0.02
Hip (cm) 109±11 100±9 0.0001
Waist-to-hip –ratio 0.91±0.08 0.96±0.08 0.0001
Whole body fat (%) 33.3±6.3 20.5±6.2 0.0001
Abdominal subcutaneous
fat (cm3)
5120±2100 2660±1300 0.0001
Intra-abdominal fat (cm3) 1060 (560-1600) 1170 (660-1850) NS
Liver fat (%) 4.0 (1.0-10.0) 3.0 (1.0-13.0) NS
Lipids
fS-triglycerides (mmol/l) 1.26 (0.87-1.71) 1.10 (0.9-1.71) NS
fS-HDL cholesterol
(mmol/l)
1.40 (1.17-1.71) 1.25 (1.10-1.57) 0.0063
fS-LDL cholesterol
(mmol/l)
2.99±0.83 3.06±0.94 NS
fS-FFA (µmol/l) 682±195 593±215 0.001
Blood pressure
Systolic BP (mmHg) 126±17 130±13 0.010
Diastolic BP (mmHg) 78±11 82±10 0.005
Other parameters
fP-glucose (mmol/l) 5.4±0.6 5.5±0.4 NS
fS-insulin (mU/l) 7.6 (4.9-12.3) 7.0 (4.5-10.0) NS
fS-C-peptide (nmol/l) 0.82 (0.6-1.0) 0.67 (0.4-1.0) NS
HbA1c (%) 5.5±0.6 5.5±0.4 NS
S-AST (U/l)§ 25 (20-32) 30 (23-40) 0.0007
S-ALT (U/l) † 24 (18-40) 35 (21-57) 0.0001
Data are shown as mean ± SD or median (25% percentile, 75% percentile).
§Reference values: 15-35 U/l for women; 15-45 U/l for men
†Reference values: 10-45 U/l for women; 10-70 U/l for men
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If adjusted for age and body mass index,
women had significantly lower liver fat
(p=0.001) and intra-abdominal fat
content (p=0.001) than men. Despite
greater obesity in women, both women
and men had similar concentrations of
fP-glucose, HbA1c, fS-insulin, fS-C-
peptide and fS-triglycerides. Blood
pressure, S-ALT and S-AST
concentrations were significantly higher
in men compared with those in women.
Characteristics of subjects with and
without the metabolic syndrome
Liver fat content. A total of 116 subjects
(43%) met the criteria for the metabolic
syndrome. Individuals with the
metabolic syndrome had significantly
higher liver fat content (median 8.2%;
interquartile range 3.2%-18.7%)
compared with those without the
metabolic syndrome (2.0%; 1.0%-5.0%,
p<0.0001). This difference remained
significant after adjustment for age,
gender, and BMI (p=0.011). In subjects
with the metabolic syndrome, liver fat
averaged 6.3% (2.0%-17.0%) in
individuals with any two components of
the metabolic syndrome, 8.2% (4.8%-
22.0%) in individuals with any three
components, and 15.5% (7.0%-23.2%)
in individuals with all four components
(p for trend <0.0001).
The regression lines representing the
relationships between liver fat and
components of the metabolic syndrome
are depicted in Figure 9. The regression
lines relating liver fat to components of
the metabolic syndrome were not
significantly different between subjects
with and without the metabolic
syndrome (data not shown). A total of
108 subjects (68 women, 40 men) had
increased liver fat content (>5.56%)
(29), and 73 (68%) of them met criteria
for the metabolic syndrome (52 women,
21 men). Inclusion or exclusion of the
subjects using antihypertensives or lipid
lowering drugs (a total of 33 subjects)
did not alter the results (data not shown).
Body composition. Figure 10 depicts the
relationships between liver fat and BMI,
whole body fat %, and intra-abdominal
fat measured by MRI. Women had less
liver fat for the same BMI and whole
body fat % than  men,  while  the
relationship between liver fat and intra-
abdominal fat were similar in both
women and men. Liver fat content was
better correlated with intra-abdominal
than abdominal subcutaneous fat in both
women and men. Both intra-abdominal
and subcutaneous fat volumes were
significantly higher in subjects with than
without the metabolic syndrome
independent of age, gender, and BMI.
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Figure 9. Relationships between liver fat and components of the metabolic syndrome.
Liver  fat  is  associated with (a) waist circumference [r=0.59, p<0.0001 (r=0.12, NS)
for women; r=0.56, p<0.0001 (r=0.26, p=0.008) for men], (b) fP-glucose [r=0.32,
p<0.0002 (r=0.18, p=0.041) for women; r=0.22, p=0.026 (r=0.053, NS) for men], (c)
fS-triglycerides [r=0.40, p<0.0001 (r=0.14, NS) for women; r=0.44, p<0.0001
(r=0.24, p=0.016) for men; r=0.42, p<0.0001 (r=0.19, p=0.003) for both women and
men], (d) fS-HDL cholesterol [r=-0.44, p<0.0001 (r=-0.24, p=0.005) for women; r=-
0.31, p=0.002 (r=-0.22, p=0.029) for men], (e) systolic BP [r=0.30, p=0.0004
(r=0.08, NS) for women; r=0.14, NS (r=-0.03, NS) for men] and (f)  diastolic  BP
[r=0.42, p<0.0001 (r=0.20, p=0.020) for women; r=0.31, p=0.0006 (r=0.15, NS) for
men]. Correlations coefficients and their significances adjusted for age and BMI are
given in parentheses. Subjects who were receiving medications for hypertension
(n=20), dyslipidemia (n=6), or both hypertension and dyslipidemia (n=7) were
excluded from these analyses. Open circles (?) and grey lines denote women (n=134),
filled circles (?), and black lines denote men (n=104) and dashed line denotes both
women and men.
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Figure 10. The relationships between liver fat and body composition features. Liver fat is
associated with (a) body mass index [r=0.54, p<0.0001 for women (n=161); r=0.52,
p<0.0001 for men (n=107)], (b) % body fat [r=0.39, p<0.0001 for women (n=148);
r=0.62, p<0.0001 for men (n=97)], (c) intra-abdominal fat [r=0.64, p<0.0001 for both
women (n=128) and men (n=93)], and (d) abdominal subcutaneous fat [r=0.43,
p<0.0001 for women (n=128); r=0.45, p<0.0001 for men (n=93)]. Symbols as in Figure
9.
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Other features. As shown in Table 8,
after adjustment for age, gender and
BMI, subjects with the metabolic
syndrome differed from those without
the syndrome with respect to all
components of the syndrome. Subjects
with the metabolic syndrome also had
significantly higher fasting serum insulin
and C-peptide concentrations than those
without the syndrome independent of
age, gender, and BMI. Indeed, of all
parameters analysed, fasting serum
insulin and C-peptide concentrations
were the strongest correlates of liver fat
content (r=0.61; p<0.0001 and r=0.62;
p<0.0001, respectively). After
adjustment for age, gender, and BMI,
these associations remained extremely
significant (fS-insulin: r=0.39, p<0.0001;
fS-C-peptide: r=0.36; p<0.0001). The
relationships could be characterized by a
single regression line since neither the
slopes nor the intercepts differed
between men and women (Fig. 11).
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Figure 11. The relationships between liver fat and fS-Insulin, fS-C-peptide and liver
enzymes. Liver fat is associated with (a) fasting serum insulin [r=0.61, p<0.0001
(r=0.39, p<0.0001) for both men (n=89) and women (n=162)] and (b) fS-C-peptide
[r=0.62, p<0.0001 (r=0.36, p<0.0001) for both men (n=76) and women (n=109)] (c)
S-ALT [r=0.39, p<0.0001 for women (n=162); r=0.44, p<0.0001 for men (n=109)],
and (d) S-AST [r=0.27, p=0.0005 for women (n=162); r=0.31, p=0.0012 for men
(n=109)] concentrations. Correlations coefficients and their significances adjusted for
age and BMI are given in parentheses. Symbols as in Figure 9.
0.1 1 10 100
1
5
10
20
30
a)
fS
-In
su
lin
 (m
U
/l)
0.1 1 10 100
0.1
0.5
1
5
b)
fS
-C
-P
ep
tid
e 
(n
m
ol
/l)
0.1 1 10 100
5
10
50
100
200
c)
Liver fat (%)
S
-A
LT
 (U
/l)
0.1 1 10 100
5
10
50
100
200
d)
Liver fat (%)
S
-A
S
T 
(U
/l)
The relationship between liver fat
content and liver enzymes. S-ALT and S-
AST concentrations were positively
correlated with liver fat in both women
and men (Fig. 11). There was no
difference between the slopes of the
regression lines relating liver fat to ALT
and AST in the two groups, but the y-
intercepts were significantly lower in
women than in men. This difference
averaged 7.3±1.1 U/l for S-ALT and
3.9±1.0 U/l for S-AST. After adjusting
for age and BMI, liver fat retained its
associations with both S-ALT (r=0.32,
p<0.0001 for women; r=0.38, p<0.0001
for men) and S-AST (r=0.31, p<0.0001
for women; r=0.28, p=0.003 for men)
concentrations.
S-ALT concentrations were elevated in
30 women (19%) and 21 men (19%), in
whom liver fat averaged 14±12% and
18±15%,  respectively  (NS).  Among  the
individuals with elevated S-ALT, 23
(46%) met the criteria for the metabolic
syndrome (13 women, 10 men). S-AST
concentrations appeared to be elevated in
34 women (21%) and 23 men (21%), in
whom liver fat averaged 14±11% and
16±13%,  respectively  (NS).  Among  the
individuals with elevated S-AST, 26
subjects (39%) were diagnosed with the
syndrome (18 women, 9 men).
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Table 8. Characteristics of subjects with and without the metabolic syndrome in Study II.
Metabolic
syndrome -
Metabolic
syndrome +
Unadjusted p-
value
p-value
adjusted for
age, gender
and BMI
N 155 116
Age (y) 35±11 42±12 0.0001
Gender (women) 82 (53%) 80 (69%) 0.008
Body composition
Weight (kg) 77.3 (69.7-87.0) 93.0 (84.0-104) 0.0001 NS
BMI (kg/m2) 25.5 (23.1-29.9) 32.3 (29.5-35.0) 0.0001
Waist (cm) 92 ±13 108±13 0.0001 0.0001
Hip (cm) 102±11 111±10 0.0001 NS
Waist-to-hip –ratio 0.91±0.08 0.97±0.08 0.0001 NS
Whole body fat (%) 24.4 (17.9-33.0) 34.7 (27.1-37.1) 0.0001 NS
Intra-abdominal fat
(cm3)
736 (491-1250) 1580 (1190-2160) 0.0001 0.011
Liver fat (%) 2.0 (1.0-5.0) 8.2 (3.2-18.7) 0.0001 0.011
Lipids
fS-triglycerides
(mmol/l)
1.00 (0.74-1.26) 1.72 (1.30-2.23) 0.0001 0.0001
fS-HDL cholesterol
(mmol/l)
1.48 (125-1.74) 1.19 (1.04-1.44) 0.0001 0.0001
fS-LDL cholesterol
(mmol/l)
2.86±0.92 3.09±0.81 0.0001 0.0001
fS-FFA (µmol/l) 614±205 686±209 0.02 NS
Blood pressure
Systolic BP (mmHg) 123±13 133±13 0.0001 0.0001
Diastolic BP (mmHg) 77±10 83±9 0.0001 0.025
Other parameters
fP-glucose (mmol/l) 5.2±0.4 5.8±0.5 0.0001 0.004
fS-insulin (mU/l) 6.0 (3.3-9.0) 11 (7.0-15.9) 0.0001 0.0001
fS-C-peptide (nmol/l) 0.58 (0.4-0.9) 0.94 (0.7-1.1) 0.0001 0.0001
HbA1c (%) 5.4±0.4 5.6±0.4 0.0001 NS
  S-ALT (U/l) 23 (18-41) 32 (22-58) 0.0006 NS
S-AST (U/l) 27 (21-36) 28 (22-58) NS NS
Data are shown as mean ± SD or median (25% percentile, 75% percentile). Abdominal
subcutaneous and intra-abdominal fat volumes were determined in 98 subjects without
and 83 subjects with the metabolic syndrome. The % whole body fat was measured in 99
subjects without and 85 subjects with the metabolic syndrome.
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6.3. Effect of liver fat on insulin
clearance (Study III)
Histologically determined vs. spectro-
scopic  liver  fat  (Fig.  12). The
relationship  between  the  %  liver  fat
determined by proton spectroscopy
(calculated from the areas under the
water and methylene peaks) and the %
fat  in  the  liver  biopsy  (%  of  biopsy
surface area consisting of fat) is shown
in Fig. 12. The units of liver fat
determined by these approaches differ
(by definition), but histological liver fat
can be calculated based on spectroscopy
from the following equation:
Liver fat by histology (%) = 3.5±10.1 +
2.2±0.5 ? Liver fat by spectroscopy (%)
Subject characteristics (Table 9). Liver
fat averaged 2% and 15% in the low and
high LFAT groups, respectively. The
low and high LFAT groups were similar
with respect to age, systolic and diastolic
blood pressure, and fS-FFA con-
centrations. The high LFAT group was
more obese and had higher fP-glucose
and S-triglyceride, and lower S-HDL
cholesterol concentrations than the low
LFAT group. FS-insulin, fS-C-peptide,
and serum liver enzyme concentrations
were  higher  in  the  high  as  compared  to
the low LFAT group independent of age,
gender, and BMI.
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Figure 12. The relationship between the percent liver fat determined by histology and
1H-MRS.
58
Table 9. Subject characteristics in Study III.
Low LFAT High LFAT Unadjusted p-
value
p-value
adjusted for
BMI
N (women) 39 (10) 41 (13)
Liver fat (%) 1.8±0.2 15.0±1.5 0.0001 0.0001
Age (y) 44±1 43±2 NS
Body composition
BMI (kg/m2) 24.9±0.5 28.4±0.6 0.0001
Waist (cm) 89±2 99±2 0.0001 NS
% fat 21.9±1.2 27.0±1.1 0.003 NS
Components of
the MS
fP-glucose
(mmol/l)
5.5±0.1 5.8±0.1 0.005 NS
fS-triglycerides
(mmol/l)
1.1±0.1 1.9±0.3 0.003 NS
fS-HDL
cholesterol
(mmol/l)
1.47±0.06 1.24±0.05 0.001 NS
Systolic BP
(mmHg)
128±2 132±2 NS NS
Diastolic BP
(mmHg)
82±2 83±2 NS NS
Other parameters
fS-insulin (mU/l) 5.1±0.3 11.0±0.8 0.0001 0.0001
fS-C-peptide
(nmol/l)
0.56±0.05 0.97±0.10 0.0001 0.017
fS-C-peptide/fS-
insulin -ratio
20.9±2.9 17.7±2.4 NS (0.07) NS (0.10)
fS-FFA (?mol/l) 610±33 660±37 NS NS
S-ALT (U/l) 27±3 73±13 0.0001 0.0001
S-AST (U/l) 27±1 45±5 0.0001 0.005
Data are shown as mean ± SEM.
Serum insulin concentrations during the
prolonged low-dose insulin infusion.
Serum insulin concentrations during the
insulin infusion were approximately
38% higher in the high as compared to
the low LFAT group (Fig. 13). The
difference could not be fully explained
by significantly higher basal serum
insulin concentrations in the high LFAT
group, as the increments in serum insulin
concentrations above basal were also
significantly and approximately 36%
higher in the high (18.8±0.9 mU/l) as
compared to the low (13.8±0.51 mU/l,
p<0.0001, Fig. 13) LFAT group
independent of age, gender, and BMI
(p=0.006).
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Figure 13. Serum insulin concentrations (a) and their increments (b) before (120 min)
and during the 240 min of insulin infusion. **, p<0.01; ***, p<0.001 for the high vs. low
LFAT groups.
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Insulin clearance. Insulin clearance was
significantly impaired in the high as
compared  to  the  low  LFAT  group
(18.0±0.67 vs. 22.9±0.80 ml/kg
FFM·min, p<0.0001). This difference
remained significant after adjusting for
age, gender and BMI (p=0.001), and
even if groups with high and low LFAT
carefully matched for age, gender, and
BMI were compared (data not shown).
Liver fat content was inversely related to
the rate of insulin clearance (r=-0.52,
p<0.0001, Fig. 14) independent of age,
gender and BMI (r=-0.37, p=0.001 after
adjusting). Additional adjustment for S-
FFA concentrations during the insulin
infusion, which were higher in the high
as compared to the low LFAT group
(402±19 vs. 297±12 ?mol/l, p<0.0001),
had no effect on this association (r=-
0.34, p=0.002). Liver fat content did not
correlate  with  fS-FFA (r=0.11,  NS),  but
was significantly correlated with S-FFA
concentrations during the insulin
infusion (r=0.55, p<0.0001) independent
of age, gender, and BMI (r=0.37,
p=0.001). Insulin clearance did not
correlate with S-FFA in the basal state
(r=-0.07, NS) or during the insulin
infusion (r=-0.18, NS). Both BMI (r=-
0.25, p=0.025) and waist (r=-0.30,
p=0.01) were significantly inversely
correlated with insulin clearance, but
these relationships became non-
significant if adjusted for liver fat.
Whole body fat % was not related to
insulin clearance (r=-0.07, NS).
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Figure 14. The relationship between liver fat content and insulin clearance. Open circles
denote women (r=-0.58, p=0.004), and closed circles denote men (r=-0.51, p<0.0001).
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Determinants of fS-insulin concentra-
tions. Liver fat content correlated
significantly with fS-insulin con-
centrations (r=0.62, p<0.0001) inde-
pendent of age, gender, and obesity
(r=0.34, p=0.002). In simple linear
regression analyses, liver fat content and
insulin clearance explained 38% and
42% of the variation in fS-insulin
concentrations, respectively. To deter-
mine the extent to which liver fat content
contributed to the variation of fS-insulin
concentrations due to impaired insulin
clearance, multiple linear regression
analyses were employed. Both liver fat
(p<0.0001) and insulin clearance
(p<0.0001) were independent determi-
nants of fS-insulin concentrations and
together explained 53% of their
variation. Thus, on the average 27% of
the variation in fS-insulin concentrations
were attributed to impaired insulin
clearance due to liver fat content.
After adjusting for the rates of insulin
clearance, liver fat content correlated
significantly with fS-insulin (r=0.43,
p<0.0001) and explained 22% of its
variation (Fig. 15). The slopes of the
regression lines were significantly
different (p=0.002).
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Figure 15. The relationships between liver fat and fS-insulin concentrations (open
triangles and the grey line, r=0.62, p<0.0001), and between liver fat and fS-insulin
concentrations adjusted for insulin clearance (closed triangles and the black line,
r=0.43, p<0.0001). The slopes of the regression lines differed significantly (p=0.002),
implying that the contribution of impaired insulin clearance to fasting hyperinsulinemia
increased as a function of liver fat.
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Hepatic insulin resistance. Rates of
hepatic glucose production did not differ
between the groups in the basal state
(3.27±0.14 vs. 2.96±0.17 mg/kg
FFM·min, low vs. high LFAT, NS).
During the insulin infusion, the rate of
hepatic glucose production was higher in
the high (0.63±0.23 mg/kgFFM·min) as
compared to the low (0.04±0.20 mg/kg
FFM·min, p=0.008) LFAT group. The %
suppression of hepatic glucose produc-
tion during the last hour of insulin
infusion was significantly correlated
with liver fat content (r=-0.40, p=0.0002,
Fig. 16) but was unrelated to insulin
clearance (r=0.19, NS). In multiple
linear regression analysis, both hepatic
insulin resistance (p<0.0001) and insulin
clearance (p<0.0001) were independent
determinants of fS-insulin concentra-
tions and together explained 52% of
their variation (p<0.0001 for ANOVA).
If liver fat content was incorporated into
these analyses as an independent
variable, hepatic insulin resistance
(<0.0001), insulin clearance (p<0.0001),
and liver fat content (p<0.0001) were
independent determinants of the fS-
insulin concentration (r2=59%, p<0.0001
for ANOVA). Additional inclusion of
fS-C-peptide did not abolish these
significances (data not shown).
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Figure 16. The relationship between % suppression of hepatic glucose production and
liver fat content. r=-0.40, p=0.0002. Symbols as in Figure 14.
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6.4. Liver fat in type 2 diabetes
(Study IV)
Subject characteristics (Table 10). Non-
diabetic subjects and type 2 diabetic
patients were equally obese and similar
with respect to age and gender. The type
2 diabetic patients had higher fS-insulin,
fS-triglyceride, and fS-FFA concentra-
tions, and lower fS-HDL cholesterol
concentrations as compared to the non-
diabetic subjects. The type 2 diabetic
patients had approximately 16% more
intra-abdominal and approximately 80%
more liver fat than the non-diabetic
subjects. The difference in liver fat
remained significant even after adjusting
for intra-abdominal fat content (p<0.05).
The type 2 diabetic patients treated with
Table 10. Subject characteristics in Study IV.
Non-diabetic
subjects
Type 2 diabetic
patients
p-value
N (women) 70 (33) 70 (33)
Age (yrs) 48±1 49±1 NS
Body composition
BMI (kg/m2) 31.2±0.6 31.6±0.6 NS
Waist (cm) 105±1 107±1 NS
% fat 30±1 31±1 NS
SC fat (cm3) 4600±270 4400±230 NS
IA fat (cm3) 1900 (1300-2500) 2200 (1600-3500) 0.02
Liver fat (%) 7.3 (3.0-17.0) 13.0 (6.0-20.5) 0.005
Glycemic parameters
fP-glucose (mmol/l) 5.6±0.1 9.3±0.3 <0.0001
HbA1c (%) 5.6±0.1 7.6±0.2 <0.0001
fS-insulin (mU/l) 8.4 (6.0-12.7) 12.0 (8.0-18.0) 0.004
Serum lipids
fS-triglycerides (mmol/l) 1.90±0.17 2.55±0.23 0.007
fS-HDL cholesterol
(mmol/l)
1.36±0.04 1.17±0.04 0.0003
fS-LDL cholesterol
(mmol/l)
3.18±0.11 2.75±0.11 0.0007
fS-FFA (?mol/l) 650±30 780±30 0.003
Blood pressure
Systolic BP (mmHg) 136±2 135±2 NS
Diastolic BP (mmHg) 85±1 83±1 NS
Liver enzymes
S-ALT (U/l) 31 (23-62) 38 (28-58) NS
S-AST (U/l) 29 (22-44) 29 (24-48) NS
AST/ALT 0.83 (0.59-1.04) 0.85 (0.68-1.05) NS
Data are shown as mean ± SEM or, for non-normally distributed data, as median
followed by the 25%th and 75%th percentiles.
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diet, metformin (MET), or the combina-
tion of insulin and metformin
(INS+MET) differed slightly with
respect to age (45±2, 55±2, 50±2 years,
diet, MET, INS+MET, p=0.003 for diet
vs. MET), whereas BMI (32.0±0.7,
30.2±1.4, 32.2±1.0 kg/m2, NS), liver fat
content (15.5% (7.0-21.0%), 9.0% (4.2-
19.5%), 14.0% (7.0-21.3%), NS), and S-
ALT concentrations (42 (29-69), 31 (21-
46),  38  (26-52)  U/l,  NS)  were  similar
between the groups.
Relationships between body composition
and liver fat content. Liver fat content
was significantly correlated with BMI
and waist circumference in the type 2
diabetic patients and in the non-diabetic
subjects (Fig. 17). At any given BMI or
waist circumference, the type 2 diabetic
patients had significantly more liver fat
than the non-diabetic subjects. The type
of antihyperglycemic therapy had no
impact on these relationships (data not
shown). At a BMI of 25 kg/m2, the type
2 diabetic patients had approximately
40% more liver fat than the non-diabetic
subjects. This difference rose gradually
as a function of BMI. For example, at a
BMI of 40 kg/m2, the type 2 diabetic
patients had 80% more liver fat than the
non-diabetic subjects. A similar
phenomenon was observed when waist
was  plotted  against  liver  fat.  For
example, at waist circumferences of 85
and 140 cm, liver fat content was 50%
and 90% higher in the type 2 diabetic
patients than in the non-diabetic
subjects, respectively. Intra-abdominal
fat was similarly related to liver fat in
both non-diabetic subjects and type 2
diabetic patients (r=0.45, p<0.0001). The
volume of subcutaneous fat did not
correlate with liver fat content in either
group.
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Figure 17. The relationships between liver fat and body composition. Liver fat content
correlates  with  (a) BMI [r=0.45, p<0.0001 for type 2 diabetic patients (regression
equation: LFAT% = 10[-0.0524±0.27 + 0.034±0.01 * BMI]); r=0.26, p=0.029 for non-
diabetic subjects (LFAT% =10[0.003±0.37 + 0.0264±0.01 * BMI])]; and (b) waist
circumference [r=0.45, p=0.0001 for type 2 diabetic patients (LFAT% = 10[-0.42±0.36 +
0.014±0.003 * Waist]); r=0.29, p=0.017 for non-diabetic subjects (LFAT% = 10[-0.42±0.52 +
0.012±0.005 * Waist])]. Open circles and grey lines denote non-diabetic subjects, and filled
circles and black lines denote type 2 diabetic patients.
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Relationships between insulin, glycemia,
lipids, and liver fat content. Liver fat
content was similarly related to fS-
insulin (r=0.55, p<0.0001), C-peptide
(r=0.40, p<0.0001), HbA1c (r=0.34,
p<0.0001), fP-glucose (r=0.29,
p=0.0006), fS-triglyceride (r=0.36,
p<0.0001) and fS-HDL cholesterol (p=-
0.31, p=0.0002) concentrations in the
non-diabetic subjects and the type 2
diabetic patients (Fig. 18).
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Figure 18. The associations between liver fat and fS-insulin concentrations and serum
lipids. Liver fat content is related to (a) fS-insulin (r=0.55, p<0.0001 for both non-
diabetic subjects and type 2 diabetic patients), (b) fS-triglycerides (r=0.36, p<0.0001 for
both non-diabetic subjects and type 2 diabetic patients), and (c) fS-HDL cholesterol (r=-
0.31, p=0.0002 for both non-diabetic subjects and type 2 diabetic patients). Dashed lines
denote both non-diabetic subjects and type 2 diabetic patients. Symbols as in Figure 17.
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Relationships between liver enzymes and
liver fat content. S-AST and S-ALT
correlated with liver fat content in both
non-diabetic subjects and type 2 diabetic
patients. The slopes of the regression
lines between S-ALT concentrations and
liver fat content differed significantly
between the non-diabetic subjects and
the type 2 diabetic patients (p=0.004).
For any given ALT, the type 2 diabetic
patients had more liver fat than the non-
diabetic subjects (Fig. 19). Liver fat
content did not differ between the groups
at low S-ALT concentrations (10-20
U/l), but was 70%, 125%, and 200%
higher in type 2 diabetic patients as
compared to controls at S-ALT
concentrations of 50 U/l, 100 U/l, and
200 U/l. At normal S-AST concentra-
tions (15-45 U/l), liver fat content was
30-70% higher in the type 2 diabetic
patients than in the non-diabetic
subjects. This increase rose gradually
with increasing S-AST concentrations,
and averaged 80% and 130% at S-AST
concentrations of 60 U/l and 100 U/l.
Serum liver enzyme concentrations did
not differ between the subjects who were
using statins as compared to those who
were not (S-AST: 29 (22-40), 29 (23-46)
U/l, NS; S-ALT: 35 (21-51), 33 (24-64)
U/l, NS). The relationship between liver
enzymes and liver fat content did not
differ between subjects who were and
were not using statins in either group
(data not shown).
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Figure 19. The relationships between liver fat content and liver enzymes. Liver fat content
associates with (a) S-AST [r=0.49, p<0.0001 for type 2 diabetic patients (LFAT% = 10[-
0.11±0.25 + 0.75±0.16 * log(S-AST)]); r=0.24, r=0.043 for non-diabetic subjects (LFAT% =
10 [0.01±0.40 + 0.54±0.26 * log(S-AST)])];  and  (b) S-ALT [r=0.66, p<0.0001 for type 2
diabetic patients (LFAT% = 10[-0.30±0.19 + 0.83±0.12 * log(S-ALT)]); r=0.26, p=0.027 for
non-diabetic subjects (LFAT% = 10[0.15±0.30+ 0.43±0.19 * log(S-ALT)])] concentrations.
Symbols as in Figure 17.
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Table 11. Liver fat content at increasing S-ALT and S-AST concentrations in the non-
diabetic subjects and the type 2 diabetic patients.
           Liver fat content
Non-diabetic
subjects
Type 2 diabetic
patients
S-ALT (U/l)
20 5.1% 6.0%
40 6.9% 10.7%
60 8.2% 15.0%
80 9.3% 19.0%
100 10.2% 22.9%
S-AST (U/l)
20 5.2% 7.3%
40 7.5% 12.3%
60 9.3% 16.7%
80 10.9% 20.8%
100 12.3% 24.5%
68
6.5 Effect of rosiglitazone on liver
fat, insulin requirements, and
hepatic insulin sensitivity in
type 2 diabetic patients with a
fatty liver (Study V)
Glycemic control, insulin requirements,
and body composition. HbA1c decreased
by 1.1±0.3%, from 8.9?0.4% to
7.8?0.3% (p=0.007) during 8 months of
Table 12. Clinical and biochemical characteristics of the patients before and after 8
months of rosiglitazone-insulin combination therapy.
Before After p-value
Body composition
Body weight (kg) 111±4 114±4 0.002
BMI (kg/m2) 36.7±1.1 37.8±1.1 0.002
Waist (cm) 120±3 125±3 NS
% fat 32.1±1.4 32.6±1.4 NS
Fat-free mass (kg) 75±2 77±2 0.03
IA fat (cm3) 3900±340 4200±360 NS
SC fat (cm3) 5500±540 6000±530 0.0002
Glycemic parameters
fP-glucose (mmol/l) 9.1±0.6 7.9±0.5 NS
fS-insulin (mU/l) 40 (15-62) 27 (11-43) NS (0.10)
Insulin dose
(IU/kg/day)
1.98±0.2 1.11±0.15 0.001
Insulin dose
(IU/kgFFM/day)
2.90±0.27 1.66±0.23 0.001
Serum lipids
fS-triglycerides
(mmol/l)
3.1±0.8 2.1±0.3 NS
fS-LDL cholesterol
(mmol/l)
2.20±0.24 2.16±0.14 NS
fS-HDL cholesterol
(mmol/l)
1.01±0.09 1.07±0.10 NS
fS-FFA (?mol/l) 716±52 597±50 0.04
Blood pressure
Systolic BP (mmHg) 144±6 142±5 NS
Diastolic BP (mmHg) 79±2 80±1 NS
Liver enzymes
S-AST (U/l) 40±5 34±5 0.04
S-ALP (U/l) 108±14 67±7 0.02
S-?GT (U/l) 51±11 27±3 0.0005
Data are shown as mean ± SEM or, for non-normally distributed data, as median
followed by the 25%th and 75%th percentiles.
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rosiglitazone therapy. Insulin dose
decreased by 89±24 IU/day (40±8%)
from 218?22 to 129?20 IU/day
(p=0.002, Fig. 20). Body weight
increased by 3.2±0.9 kg, which was due
to an increase in fat-free mass (1.7?0.7
kg) and fat mass (1.6?0.7 kg).
Subcutaneous but not intra-abdominal
fat increased significantly when
measured with MRI (Table 12). Insulin
regiments  at  the  end  of  the  study
remained unchanged.
Liver fat content and serum liver enzyme
concentrations. Liver fat content
decreased  by  46±9 %  from  20±3 %  to
11±3% (p=0.0002, Fig. 20). S-ALT, S-
AST, S-?GT, and S-ALP concentrations
also decreased significantly (Table 12).
The % change in liver fat correlated with
the % changes in S-ALT (r=0.50,
p=0.08), S-AST (0.63, p=0.02), and S-
?GT concentrations (r=0.72, p=0.01).
Associations between liver fat content
and glycemic parameters. The % change
in liver fat content was positively
correlated with the % change in insulin
dose (r=0.66, p=0.014) and almost
significantly with that in HbA1c (r=0.53,
p=0.06, Fig. 21).
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Figure 20. Effects of addition of rosiglitazone on (a) liver fat content, (b) HbA1c,  (c)
insulin dose, and (d) S-ALT.  *, p?0.05; **, p<0.01; ***, p<0.001. ?, before; ?, after the
rosiglitazone-insulin combination therapy.
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Figure 21. The relationship between the % change in liver fat content and (a)  the  %
change in the suppression of hepatic glucose production, (b) the % change in HbA1c, and
(c) the % change in insulin dose by 8 months of rosiglitazone-insulin combination therapy.
Insulin sensitivity. Steady-state plasma
glucose concentrations during euglyce-
mia (240-360 min) averaged 8.1?0.05
and 8.2?0.04 mmol/l before and after
rosiglitazone (NS). Fasting serum free
insulin decreased by 48% (Table 12).
Serum free insulin concentrations (60-
360 min) averaged 77 mU/l (47-106
mU/l, median, interquartile range) vs. 59
mU/l (39-93 mU/l), respectively
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(p=0.07). The increment in serum free
insulin concentrations was similar before
(28 mU/l [15-34 mU/l]) and after (25
mU/l [13-36 mU/l], NS) rosiglitazone
therapy, implying that insulin clearance
remained unchanged (17 ml/kgFFM·min
[13-29 ml/kgFFM·min] vs. 16
ml/kgFFM·min [13-26 ml/kgFFM·min],
NS).
Rates of basal hepatic glucose
production were similar before
(2.82±0.25 mg/kgFFM·min) and after
(2.33±0.33 mg/kgFFM·min, NS) rosi-
glitazone treatment. During the insulin
infusion, the rate of hepatic glucose
production decreased (1.69±0.25 vs. 0.61
± 0.24 mg/kgFFM · min,  p=0.007), and
the % suppression by insulin increased
from -40±7% to -89±12% (p=0.001) by
rosiglitazone. The change in the %
suppression of hepatic glucose
production correlated positively with the
% change in liver fat content (r=0.76,
p=0.003). The rate of basal glucose
disposal decreased from 2.90±0.24 to
2.06±0.27 mg/kgFFM·min (p=0.028),
while the rate of insulin-stimulated
glucose disposal remained unchanged
(2.87±0.16 vs. 2.48±0.18 mg/kg
FFM·min, NS).
Energy expenditure and substrate
oxidation rates. During insulin therapy,
energy expenditure in the basal
(83.2±3.2 J/kgFFM·min vs. 78.2±2.1
J/kgFFM·min, p=0.05) and insulin-
stimulated (80.1±3.0 vs. 75.1±1.9 J/kg
FFM·min, p=0.017) states decreased
significantly by rosiglitazone. The rate
of lipid oxidation during insulin
stimulation decreased significantly
(1.81±0.12 vs. 1.51±0.12 mg/kg
FFM·min, p=0.04). Rates of carbohy-
drate and protein oxidation remained
unchanged (Fig. 22).
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Figure 22. Effects of 8 months of the addition of rosiglitazone on rates of energy
expenditure in the basal state (a) and during hyperinsulinemia (b). ?, protein oxidation; ?,
carbohydrate oxidation [grey], ?, lipid oxidation. *, p?0.05.
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7. DISCUSSION
Although the epidemic of obesity has
been accompanied by an increase in the
prevalence of the metabolic syndrome,
not all obese develop the syndrome, and
even lean individuals can be insulin
resistant (462). Hepatic fat accumulation
is related to hepatic insulin resistance
(355, 379), which in turn leads to
hyperglycemia (355, 379), hyper-
triglyceridemia (5, 6), and a low HDL
cholesterol concentration (265), compo-
nents included in the current definition
of the metabolic syndrome by IDF (9).
This raises the possibility that fat
accumulation in the liver distinguishes
between those who do and do not
develop the metabolic syndrome. The
present study aimed to investigate the
role of hepatic fat accumulation in the
metabolic syndrome and type 2 diabetes.
7.1. Liver fat vs. IMCL in relation to
the metabolic syndrome (Study I)
In Study I, liver fat was 5-fold higher in
subjects with than without the metabolic
syndrome independent of obesity, while
no differences in IMCL content could be
observed between those with and
without the syndrome. The fatty liver
was shown to be insulin resistant when
measured directly. These data suggest
that in the present study group,
intrahepato- rather that intramyocellular
lipid accumulation was a marker of the
metabolic syndrome, i.e. increased
triglycerides and decreased HDL
cholesterol, as well as hyperinsulinemia
and low adiponectin.
We found obesity to be, consistent with
previous data, associated with increased
IMCL (158, 418), decreased VO2max
(81), and whole body insulin sensitivity
(473) (Fig. 7). Since IMCL is increased
by both enhanced physical fitness (190,
418, 437) and obesity (158, 418), the
lack of a relationship between IMCL and
muscle insulin sensitivity is not
surprising. As in the present study,
Thamer et al found neither VO2max nor
insulin sensitivity to be associated with
IMCL (418). However, further analyses
revealed a significant positive associa-
tion between VO2max and IMCL in lean
but not obese subjects (418). In Study I,
IMCL  was  not  related  to  VO2max,
possibly because the study subjects
covered  a  wide  range  of  obesity  while
none participated in regular physical
exercise. Nevertheless, BMI was
inversely related to VO2max expressed
per fat free mass (Fig. 7). This may
explain why IMCL was not inversely
related to muscle insulin sensitivity,
although VO2max was an independent
determinant of muscle insulin sensitivity
(Fig. 7).
Hepatic fat content has been shown to
associate with insulin resistance of
hepatic glucose production (268, 355,
379). We now extended these findings to
show that liver fat is associated with
hepatic insulin resistance in the absence
of  changes  in  IMCL,  and  that  liver  fat
and IMCL were not correlated. This
implies that sites of intracellular
triglyceride accumulation exhibit
interindividual variation. It is notewor-
thy that although liver fat is a marker of
hepatic insulin resistance, it is highly
unlikely that the metabolically inert
triglycerides mediate the impairment in
insulin action (284, 403). Lipid
intermediates which increase as a
function of intracellular lipid stores, such
as diacylglycerols (286) or ceramides
(180), are likely to be responsible.
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Regarding the reasons why liver fat
associated with features of the metabolic
syndrome, we have previously shown
that failure of insulin to suppress hepatic
VLDL production results in hyper-
triglyceridemia and a low HDL
cholesterol concentration (265), and that
VLDL overproduction rather than
impaired clearance correlates with liver
fat content (5). Resistance to insulin
suppression of triglyceride production,
although not measured in this study, is
therefore a likely explanation for the
finding of higher serum triglycerides and
lower HDL cholesterol in the high as
compared to the low LFAT groups.
Intrahepatic fat content is frequently
referred to as an additional feature of the
metabolic syndrome (435). In the present
study, liver fat was 5-fold higher in
subjects with than without the metabolic
syndrome independent of obesity. On the
other  hand,  no  differences  in  IMCL
content could be observed between
subjects with and without the metabolic
syndrome. Our findings suggest that
depots of lipid accumulation in the liver
and skeletal muscle do not contribute in
an interactive manner to the metabolic
syndrome.
In Study I, fasting serum FFA concentra-
tions were not associated with liver fat
or IMCL content, but they remained
significantly higher during the low-dose
insulin infusion in subjects with high
liver fat content independent of obesity.
This finding is in keeping with previous
studies  in  patients  with  NAFLD  as
compared to weight-matched healthy
controls (55). The reason for the lack of
any relationship between fasting serum
FFA and liver fat content is unclear.
Possibly, higher FFA during hyper-
insulinemia could reflect insulin
resistance of lipolysis (435). In keeping
with differential regulation of serum
FFA basally and during hyper-
insulinemia, basal lipolysis is unaltered
in  HSL-null  mice  (446).  There  are,
however, no human data describing
alterations in FFA fluxes across the
splanchnic bed, and therefore alterations
in FFA utilization in subjects with high
vs. low liver fat content cannot be
excluded.
In conclusion, intrahepatocellular rather
than intramyocellular fat associates with
the metabolic syndrome, characterized
by increased triglyceride and decreased
HDL cholesterol concentrations, inde-
pendent of obesity. This may in part be
because IMCL is not correlated with
muscle insulin sensitivity in subjects
whose muscle insulin sensitivity is
regulated by both obesity and physical
fitness, as in the present study and that
of  Thamer  et  al  (418).  The  data  thus
suggest that ectopic fat deposition in the
liver may be a useful additional marker
of the metabolic syndrome, although
there is a need to identify novel simple
circulating markers which would be
suitable for use in the clinic as measures
of liver fat.
7.2. Liver fat and the metabolic
syndrome (Study II)
To our knowledge, this is the first study
to quantitate the amount of liver fat in
subjects with and without the metabolic
syndrome. Liver fat content, measured
by the most accurate method available to
date (462), was 4-fold higher in subjects
with than without the metabolic
syndrome independent of age, gender,
and BMI. Liver fat content increased in
proportion to the number of components
of the metabolic syndrome. Each
component of the syndrome correlated
with liver fat content. Of all measures of
insulin resistance, the best correlates of
liver fat were fasting serum insulin and
C-peptide concentrations.
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The study population did not represent a
random sample but rather represented a
non-diabetic group which had been
recruited for metabolic studies using
similar criteria: (i) age 20 to 65 years;
(ii) healthy except for possible obesity;
(iii) no known acute or chronic disease
except for hypertension and
hyperlipidemia based on history and
physical examination and standard
laboratory tests; (iv) alcohol consump-
tion less than 20 g per day. In subjects
without the metabolic syndrome liver fat
content averaged 2.0% (1.0%-5.0%),
which corresponds closely to what was
considered  normal  in  the  Dallas  Heart
Study (409). In this population-based
study, in which liver fat was measured in
2349 subjects using proton magnetic
resonance spectroscopy, the upper limit
of hepatic TG content was 5.56%.  In
patients with the metabolic syndrome in
the present study, median liver fat
content was 8.2% and thus exceeded this
limit. The increase could not be
explained by age or gender, and it was
independent of BMI. This is in
agreement with previous studies in
which the relationship between liver fat
and obesity has been weak (5) and non-
existent (379, 425) if subjects with a
narrow range of BMI have been studied.
Here we show that liver fat content
correlated with all components of the
metabolic syndrome as defined by the
newest IDF criteria. The best correlate
was waist circumference, which could
explain 31-35% of the variation in liver
fat  content.  Waist  is  thought  to  be  a
surrogate for intra-abdominal fat, and
when measured directly using MRI,
intra-abdominal fat volume explained
38-44%  of  the  variation  in  liver  fat
content.  In  the  study  of  Kelley  et  al
(214), which included 83 type 2 diabetic
patients and 27 non-diabetic subjects,
visceral adipose tissue and the liver to
spleen attenuation ratio (L/S ratio) were
significantly correlated (r=0.57), i.e.
visceral adipose tissue explained 32% of
the variation in  the L/S ratio,  which is  a
qualitative rather than quantitative
marker  of  liver  fat.  Consistent  with  the
data of Kelley et al in type 2 diabetic
patients, in which BMI explained 18% of
variation in the L/S ratio, we found BMI
to explain 29% and 27% of the variation
of liver fat in women and men,
respectively. Taken together, these data
suggest that visceral adipose tissue,
while possibly important, is not the only
factor contributing to the variation in
liver fat content. Indeed, according to
catheterization studies, the contribution
of visceral fat to hepatic FFA delivery
averaged 10% and did not exceed 50%
of the total amount of FFA reaching the
liver (292).
Liver fat was significantly positively
correlated with serum triglycerides and
similarly negatively correlated with
HDL cholesterol. This has previously
been documented in smaller studies
(397, 452). The increase in serum
triglycerides is known mainly to reflect
insulin resistance of inhibition of hepatic
VLDL production (5). High triglycerides
in turn lower HDL cholesterol (294). In
addition, linear regression analysis
revealed a weak but significant
association between liver fat content and
both systolic and diastolic blood
pressure. The poor correlation may be
due to use of a single measurement of
blood pressure which is neither reliable
nor reproducible (20). In keeping with
this, in a previous study both 24-hour
systolic and diastolic blood pressures
were elevated in women with high
compared  with  those  with  low  liver  fat
content independently of age and BMI
(425).
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Liver enzyme concentrations have
previously been shown to reflect hepatic
steatosis (30, 304). Although we found a
significant correlation between liver fat
and both S-ALT and S-AST
concentrations, other markers, such as
fasting serum C-peptide, more accurately
reflected liver fat content in these non-
diabetic subjects. S-ALT concentrations
explained only 15-19% of liver fat,
implying that this enzyme is a poor
marker  of  liver  fat.  There  were  no
differences in the slopes of the
regression lines relating liver fat and
liver enzymes between women and men,
but the intercepts differed significantly.
This observation is consistent with the
lower reference ranges for S-ALT and S-
AST in  women  compared  with  those  in
men (334). Smaller liver size (243) and
decrease in S-ALT by female
reproductive hormones (276, 401) could
contribute to lower S-ALT
concentrations in women than in men.
Of all parameters analysed, fasting
serum  insulin  was  the  marker  most
closely related to liver fat content. This
strong association may be explained by
the decrease in hepatic insulin clearance
in subjects with increased hepatic fat
content (159, 400). Indeed, a 51%
decrease in liver fat achieved by
rosiglitazone therapy has been shown to
increase insulin clearance by 20% (424).
However, C-peptide, which is not
degraded by the liver (328), was also a
strong correlate of liver fat. This
documents that the increase in serum
insulin is not just a consequence of
diminished insulin clearance. Previously,
fasting serum insulin has been included
in the definition of the metabolic
syndrome (10), but because of assay
standardization problems, this parameter
was excluded from the latest metabolic
syndrome criteria. Still, within a given
laboratory, increased fasting serum
insulin and C-peptide concentrations
could be useful markers of the fatty liver
independently of age, gender, and BMI.
Taken together, we found liver fat to be
on the average 4-fold increased in
middle-aged non-diabetic subjects with
the metabolic syndrome. Components of
the syndrome were significantly
correlated with liver fat even
independently of age, gender, and BMI.
Although the interindividual variation in
liver fat ranged considerably, the mean
increase (8.2% vs. 2.0%) cannot be
detected by routinely available clinical
tools  such  as  S-ALT.  Nevertheless,  the
present data strengthen the idea that
those obese and non-obese subjects who
accumulate excess fat in the liver are the
ones who develop the metabolic
syndrome.
7.3. Insulin clearance and liver fat
(Study III)
The liver is a major site of insulin action,
clearance and degradation (116). The
majority (80%) of endogenously
secreted insulin is cleared by the liver,
15% by the kidney, and 5% by muscle
(137). Of intravenously infused insulin,
50%, 30%, and 10%, respectively, are
cleared by these tissues (137). Liver fat
is closely correlated with fasting serum
insulin concentrations (229, 452), but the
extent to which impaired insulin
clearance due to hepatic fat accumula-
tion contributes to hyperinsulinemia has
not previously been determined. In the
present study, we found hepatic fat
accumulation to be an important and
independent regulator of insulin
clearance, as measured by the euglyce-
mic hyperinsulinemic clamp technique,
i.e. after i.v. insulin administration.
Impaired insulin clearance due to
increased liver fat content explained on
the average 27% of the variation in fS-
insulin concentrations. The slopes of the
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regression lines relating liver fat and fS-
insulin and fS-insulin corrected for
insulin clearance differed significantly,
implying that the contribution of
impaired insulin clearance to fasting
serum insulin concentrations increases
with increasing liver fat content. Direct
measurement of hepatic insulin sensitiv-
ity  showed  that  liver  fat  was  also
associated with hepatic insulin resis-
tance.
Hepatocytes loaded with triglycerides
exhibit impaired insulin clearance in
vitro (400). In a study of 46 non-diabetic
subjects  with a  wide range of  adiposity,
the liver-to-spleen attenuation ratio, a
qualitative marker of liver fat, has been
found to be inversely related to insulin
clearance (159). However, in this study,
insulin clearance was not adjusted for %
body fat (159), and it thus remained
unclear whether the apparent decrease in
insulin clearance in those with high liver
fat was due to liver fat or to differences
in the insulin distribution space between
the obese subjects with high liver fat as
compared to the non-obese subjects with
less liver fat. Since fat is essentially
water-free, the plasma volume per body
weight unit decreases with increasing %
body fat (11). Thus, when insulin is
infused at a rate which is calculated
based on kg body weight or body surface
area (159), insulin clearance will be
lower in obese than in non-obese
subjects (474). In Study III, we found
that during a prolonged low-dose insulin
infusion, serum insulin concentrations
and insulin increments were approxi-
mately 40% higher in subjects with high
LFAT independent of age, gender, and
BMI. Consequently, insulin clearance
was considerably impaired in the high as
compared to the low LFAT group.
Although it would have been ideal to
study weight-matched groups with high
and low LFAT, the present data suggest
that liver fat impairs insulin clearance
independent of BMI.
It has been proposed that FFA-mediated
reduction in insulin clearance is an
adaptive mechanism which exacerbates
hyperinsulinemia to overcome peripheral
insulin resistance (247). In a previous
study, Wiesenthal et al showed that in
dogs hepatic insulin extraction is
impaired when serum FFA concentra-
tions are elevated to supraphysiological
concentrations by infusions of a soy-
based lipid emulsion and heparin during
euglycemic hyperinsulinemia (457). In
humans, a day-long infusion of a soy-
based lipid emulsion and heparin (S-
FFA ~500-800 ?mol/l) has been shown
to reduce insulin clearance in subjects
with a  family history of  type 2 diabetes
(212). In Study III, where no exogenous
FFA were infused, fasting FFA were in
this range but were uncorrelated with
both liver fat and insulin clearance.
However, the fasting serum insulin
concentrations were 2-fold higher in the
high as compared to the low LFAT
group. This difference in insulin levels
in the face of similar FFA concentration
mostly likely reflects adipose tissue
insulin  resistance  and  may  make  it
difficult to observe a relationship
between fasting FFA and insulin
clearance.
Previous studies have shown that insulin
clearance is decreased in obesity (279,
389). It has also been suggested that
intra-abdominal rather than subcutane-
ous fat influences splanchnic insulin
clearance (312). Moreover, insulin
clearance increases by weight loss (327).
The decrease in insulin clearance has
also been observed in insulin-resistant as
compared to age- and BMI-matched
insulin-sensitive subjects (203).  How-
ever, the causes of the variation in
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insulin clearance have not been
determined in these studies. Our data
suggest  that  liver  fat  content  is  an
important contributor to the variation in
insulin clearance and could contribute to
decreased insulin clearance in obesity
(279, 389). Liver fat could also explain
why weight-matched groups differing
with respect to insulin sensitivity also
may exhibit differences in insulin
clearance. Furthermore, liver fat content
is better correlated with intra-abdominal
than subcutaneous fat (229, 452). We
have previously shown that a decrease in
liver fat content, achieved by
rosiglitazone therapy, increases insulin
clearance and enhances hepatic insulin
sensitivity significantly independent of
body weight in type 2 diabetic patients
(424).  In  addition,  liver  fat  can  be
considerably reduced by weight loss (79,
423). Thus, interventions which change
liver fat also appear to change insulin
clearance.
In the present study, on the average 27%
of the variation in fS-insulin concentra-
tions could be explained by those in
insulin clearance when fasting insulin
concentrations were measured in
subjects whose liver fat content varied
over a wide range. The contribution of
impaired insulin clearance to fasting
hyperinsulinemia increased as a function
of liver fat (Fig. 15). This implies that
indirect measures of insulin sensitivity,
such as the homeostatic model
assessment of insulin resistance
(HOMA-IR) (271), overestimate insulin
sensitivity in non-diabetic individuals in
whom insulin resistance is associated
with, or perhaps due to a fatty liver
rather than e.g. skeletal muscle. Note
that the C-peptide-to-insulin –ratio
differed only marginally between the
groups, possibly because C-peptide
clearance is  also  subject  to  interindivi-
dual variation (124), while was not
quantitated in this study. Although
serum C-peptide concentrations during
the insulin infusion was not measured in
Study  III,  it  has  previously  been  shown
that serum C-peptide concentrations fall
significantly already after 60 min of
exogenous insulin infusion at the rate of
0.25 mU/kg·min and do not change at
the higher insulin infusion rates (94). We
showed by direct measurement of insulin
sensitivity that hepatic insulin sensitivity
decreases as a function of liver fat. This
insulin resistance represented an
underestimate of hepatic insulin
resistance, as insulin concentrations
increased with increasing liver fat
content.
In conclusion, a fatty liver is associated
with both hepatic insulin resistance and
impaired insulin clearance. The impact
of liver fat on insulin clearance increases
as a function of liver fat. This implies
that indirect measures of insulin
sensitivity, such as fasting insulin,
overestimate hepatic insulin resistance
the more fat the liver contains.
7.4. Liver fat and type 2 diabetes
(Study IV)
In Study IV, we used state-of-the-art –
methodology for quantification of liver
fat in a large group of type 2 diabetic
patients and carefully age- and gender-
matched equally obese non-diabetic
subjects. Liver fat content was on the
average  80%  higher  in  the  type  2
diabetic patients than in the non-diabetic
subjects. This difference was not
influenced by the type of anti-
hyperglycemic treatment. Somewhat
unexpectedly, S-ALT and S-AST were
not  related  to  liver  fat  similarly  in  the
diabetic and non-diabetic subjects. Both
S-ALT and S-AST underestimated liver
fat  content  in  type  2  diabetic patients.
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This underestimation became more
pronounced at increasing concentrations
of both S-ALT and S-AST.
In  many  previous  studies,  liver  fat
content, measured by proton magnetic
resonance spectroscopy, has been found
to exceed the upper limit of normal
hepatic TG content (5.56%) (409) in
type 2 diabetic patients. However,
except for one study which included 10
non-diabetic controls (214), these studies
had either no control group  (21, 63, 204,
273, 355, 424) or the controls were not
matched for body weight (5, 319). It has
thus remained unclear whether the
increase in liver fat content has just been
a consequence of obesity in type 2
diabetic patients. Study IV suggests that
type 2 diabetic patients have more liver
fat at any given BMI than non-diabetic
subjects, and that the difference in liver
fat content between the groups increases
with increasing obesity. In keeping with
Kelley et al (214), intra-abdominal fat
was similarly related to liver fat in both
type 2 diabetic patients and non-diabetic
subjects, and the type 2 diabetic patients
had more intra-abdominal fat than the
non-diabetic subjects.
The higher liver fat content in the type 2
diabetic patients could contribute to
diabetic dyslipidemia. The fatty liver
overproduces VLDL particles in both
non-diabetic subjects and type 2 diabetic
patients, which, in the face of unchanged
VLDL clearance, increases serum
triglyceride concentrations (5). Hyper-
triglyceridemia in turn leads to low
HDL-cholesterol concentrations (294).
The similar relationship between
triglycerides and HDL cholesterol
concentrations and liver fat content in
the diabetic patients and non-diabetic
subjects (Fig. 18) combined with the
kinetic study (5) suggest that excess liver
fat indeed contributes to diabetic
dyslipidemia.
An intriguing observation in the present
study was that the type 2 diabetic
patients had 40 to 200% more liver fat at
the  same  S-ALT  and  S-AST
concentrations than the non-diabetic
subjects (Table 11). Both enzymes thus
underestimate liver fat in type 2
diabetes. Both S-ALT and S-AST
increase in response to hepatocyte
damage until hepatocytes are lost and
cirrhosis develops (82, 234). To what
extent the lower enzyme levels reflect a
difference in hepatocellular damage
cannot be determined from the present
study.
It is important to develop tools to
diagnose a fatty liver in type 2 diabetic
patients, because NASH is more
common in type 2 diabetic patients than
in non-diabetic subjects (118, 176), and
can progress to cirrhosis and liver failure
(128). The present data suggest that if
assessed using S-ALT or S-AST, hepatic
steatosis is underestimated in type 2
diabetic patients compared to equally
obese non-diabetic subjects. There is
thus  a  need  to  develop  new  serum
markers  of  steatosis  to  complement  S-
AST and S-ALT which have been used
in the clinic for almost 50 years (211).
7.5. Treatment of type 2 diabetic
patients with a fatty liver with PPAR?
agonists (Study V)
In Study V, we hypothesized that
patients requiring exceptionally high
insulin doses might respond particularly
well to PPAR? agonist treatment. During
eight months of rosiglitazone therapy,
HbA1c decreased  significantly  despite a
40% reduction in the insulin dose. Liver
fat content decreased by 50%, and
hepatic    insulin    sensitivity    increased
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significantly. The changes in liver fat            circumference respond best to PPAR?
content correlated with both decreases in
insulin requirements and increase in
hepatic insulin sensitivity.
Due to the invasive measurements
performed, it was not ethically possible
to study a time-control group. A ‘study
effect’ could thus have contributed to the
results, which is a potential limitation.
However, we have previously shown
that addition of metformin alone for 4
months has no effect on liver fat content
(424), while rosiglitazone alone
decreases liver fat by 50% (424). Given
that insulin requirements correlate
closely and linearly with hepatic fat
content (204, 355), and S-ALT predicts
insulin requirements independent of
BMI (472), one could predict insulin
requirements to decrease by 50% if liver
fat decreases by 50%. This indeed
happened after patients had been treated
with  stable  insulin  doses  for  2  years.
These considerations make it likely that
the changes were due to rosiglitazone
rather than time, metformin, or
continued insulin therapy.
In  Study  V,  liver  fat  content  was
increased in each patient, and exceeded
its upper limit of normal defined as 5.6%
TG by 1H-MRS (409). In the previous
PPAR? agonist insulin combination
studies, the decrease in insulin doses
averaged 13 IU/day (32, 54, 89, 147,
181, 272, 329, 342), which is much less
than the 90 IU/day in the present
patients. In keeping with the present
results, in previous studies which had the
highest baseline insulin doses, the %
reduction  were  also  the  greatest  (54,
483). In these clinical studies, liver fat
content was not measured. Heterogenity
analyses from DREAM (114) and
ADOPT (206) have suggested that
patients    with    a    large    waist
agonist treatment. Waist circumference
is tightly correlated with liver fat content
(229, 452). These data support the idea
that patients with a fatty liver respond
particularly well to PPAR? agonists.
In Study V, no improvement in
peripheral insulin sensitivity, as
determined from glucose rate of
disappearance, was observed. However,
given that low physiological insulin
infusion rates are optimal for assessment
of hepatic rather than peripheral insulin
sensitivity (96, 135, 348, 478), the lack
of improvement in insulin-stimulated
glucose disposal was not unexpected.
When glycemic control is improved, the
energy need for glucose production in
the liver decreases (264). The
improvement in glycemic control is
likely to be at least one reason for the
decrease in energy expenditure found in
the present study. When calculated from
our previous data (264), the predicted
change in the basal metabolic rate due to
changes in fasting glucose and body
weight in the present study corresponds
to 6.3±19 J/kgFFM·min, which is not
different from the observed change
(5.2±2.3 J/kgFFM·min). The increase in
body weight, which accompanies
reduction in glucosuria, tends to increase
energy expenditure, but is not sufficient
to keep net energy expenditure
unchanged (264). Consistent with
previous data regarding PPAR? agonists
(22), weight gain (3.2 kg) was greater
than would be expected from
improvement in glycemic control (1.5-
2.0 kg/1% decrease in HbA1c (264)).
Weight gain was due to a roughly
similar increase in fat free mass and fat
mass, in keeping the data showing
improved glycemia to increase
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predominately fat free mass (204) and
PPAR? agonist mainly fat mass (22).
Adverse effects of TZDs include fluid
retention and the risk of heart failure
(113, 206). A recent meta-analysis
suggested rosiglitazone use to
significantly increase the risk of
myocardial infarction (295), although
there is no randomized adequately
powered  clinical  trial  to  support  this
finding (182). In Europe, combination
therapy with insulin and PPAR? agonists
is contraindicated because of an
increased risk of heart failure
(http://www.emea.europa.eu/). In the
PROactive study, a controlled study of
5238 type 2 diabetic patients at high risk
of cardiovascular events randomized to
receive either pioglitazone or placebo,
31% of patients were treated with
insulin, but it is unknown whether the
rate of cardiovascular events differed
between insulin-treated and insulin-
naive patients using pioglitazone (113).
Because of the increased risk of heart
failure, we performed echo-
cardiographies in all patients prior to
their participation to exclude heart
failure at baseline.
In conclusion, we have shown that type
2 diabetic patients who are poorly
controlled despite using unusually high
doses of insulin, do respond to
rosiglitazone. We suggest the main
mechanism underlying improved
glycemic control despite reduced insulin
requirements is enhanced hepatic insulin
sensitivity. At least in monotherapy
studies,  pioglitazone  is  as  effective  as
rosiglitazone (463) and may be
associated with a better cardiovascular
outcome during long-term treatment than
rosiglitazone (113, 206).
Taken together, Studies I-V suggest that
accumulation of fat in the liver is an
inherent component of the metabolic
syndrome and type 2 diabetes. Increased
fat accumulation in the liver is a marker
of hepatic insulin resistance and a close
correlate of all components of the
metabolic syndrome independent of
obesity. Subjects with high liver fat
content are hyperinsulinemic because of
both impaired hepatic insulin sensitivity
and insulin clearance. The contribution
of impaired insulin clearance to fasting
serum insulin concentrations increases
with increasing liver fat content. Given
that insulin action in the fatty liver is
impaired, agents which reduce liver fat
content may be particularly efficient for
the treatment of type 2 diabetic patients.
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8. SUMMARY AND CONCLUSIONS
I) Fat accumulation in the liver rather than in skeletal muscle is associated with features
of the metabolic syndrome, i.e. increased fS-triglycerides and decreased fS-HDL
cholesterol, and with hyperinsulinemia and low adiponectin concentrations. The fatty
liver has been shown to be insulin resistant.
II) Liver fat content is 4-fold higher in subjects with the metabolic syndrome as
compared to those without the syndrome, independent of age, gender, and BMI. Of other
markers, fS-C-peptide is the strongest correlate of liver fat.
III) Increased liver fat is associated with both impaired insulin clearance and hepatic
insulin resistance. Hepatic insulin sensitivity is related to liver fat content independent of
insulin clearance. This implies that indirect indices of insulin sensitivity, such as HOMA-
IR, overestimate insulin resistance in subjects with high liver fat content.
IV) Type 2 diabetic patients have 80% more liver fat than age-, weight-, and gender-
matched non-diabetic subjects. S-ALT underestimates liver fat in type 2 diabetic patients.
V) Rosiglitazone may be particularly effective in type 2 diabetic patients who are poorly
controlled despite using high insulin doses. The mechanisms are likely to involve reduced
liver fat and enhanced hepatic insulin sensitivity.
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